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1 INTRODUCTION 
 
Continuous hemofiltration (CHF) therapy is a treatment procedure, which is performed 
for acute renal failure in patients in intensive care units. Using this treatment modality 
patients are treated with one hemofilter for several days.  A crucial issue in CHF is how 
long the hemofilter membranes can maintain their initial properties to separate water 
and specific toxins from blood of the patients. 
In this study the permeation characteristics of peptides is evaluated during long-term 
continuous hemofiltration therapy.
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2 THEORETICAL BACKGROUND 
 
CHF is a blood cleansing therapy where toxins are continuously removed from blood 
using artificial membranes and an extracorporeal blood circuit. The artificial 
membranes are inserted in artificial blood hemofilters. CHF is mainly used in intensive 
care medicine in patients with acute renal as well as non-renal diseases. Because of its 
continuous application for several days, CHF resembles more to the continuous blood 
cleansing of the natural kidneys than intermittent blood cleansing, used for treatment of 
chronic kidney disease. 
 
2.1 Structure and function of the human kidney 
 
The main function of healthy kidneys is to 
eliminate waste products (uremic toxins) from 
blood and to regulate salt and water excretion 
to maintain a constant extracellular fluid 
volume, electrolyte composition, pH and 
osmolarity. 
The kidneys in a healthy person are bean-
shaped, about 10 cm and 6.5 cm wide, located 
near the vertebral column at two sides of the 
back. Each kidney comprises an outer cortex 
and an inner medulla, the pelvis and the 
ureter. Blood enters the glomerulum by an 
afferent arteriole and exits via an efferent 
venole. Urine is produced by filtration, 
reabsorption and excretion of water and 
solutes. The remaining fluid left in the distal             
Figure 1: Structure of a nephron.  tubule enters a collecting duct, which extends 
through the renal cortex and is transferred via the ureter to the bladder where it is 
emptied several times during one day via the urethra. Healthy kidneys produce 0.5 to 
3.0 l of urine per day, containing all waste products that have to be removed from the 
body. 
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The main functional unit of the kidney is the nephron. Each kidney contains about one 
million nephrons. One nephron consists of the glomerulum and the tubule. The 
glomerulum is located in the renal cortex and consists of a bundle of 30 capillaries 
surrounded by a double-walled capsule (Bowman’s capsule). Both kidneys are fed with 
blood at a flow rate of 20% of cardiac output via the renal artery. Filtration takes place 
inside the glomerulum through capillary loops, with length shorter than 5 mm and a 
diameter of 10 µm, transmembrane pressure (TMP) of 7 ~ 15 mmHg at a rate of 120 ~ 
140 ml/min (180 l/day) through 1.5 m2 of total glomerular surface area [35, 111]. The 
filtrate which is also termed primary urine, contains solutes with a molecular weight 
(MW) < 60 000. The filtration membrane in the glomerulum is highly permeable to 
water, small solutes and ions.  It is impermeable to albumin (MW 68 000) and all blood 
components larger than albumin. The barrier function for larger molecules is based on 
size, shape and net charge. Excretory kidney function is most commonly evaluated by 
measuring the glomerular filtration rate (GFR). This can be done by measuring a 
substance in blood and urine, which is filtered in the glomerulum with a sieving 
coefficient of 1.0 and neither metabolized or reabsorbed or secreted in the renal tubule 
like creatinine or inulin. The clearance (K) of creatinine has been found as the most 
convenient clinical measure of GFR. 
Kcr= (Vu • Cu) / Cb                                     (Eq. 1) 
Kcr = creatinine clearance, Vu: volume of urine per time, Cu: concentration of creatinine 
in urine, Cb:  concentration of creatinine in plasma water 
The tubule mainly takes the function of reabsorption of water and all substances, which 
are important to the body like electrolytes, buffer substances, glucose and amino acids. 
Some substances like organic ions are also secreted from the blood into the tubule. 
In addition to excretory and regulatory function the kidneys also produce hormones 
(e.g., erythropoietin, aldosterone, 1.24OH cholecalciferol) and hormone activators 
(renin).  
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2.2 Clinical conditions requiring blood purification therapy 
 
Renal failure occurs either as acute or end stage renal disease. Acute renal failure (ARF) 
in most cases is reversible and due to an acute disease like shock, sepsis, multiorgan 
failure and injury by nephrotoxic substances. It is always treated in intensive care units 
of hospitals for some days or weeks.  
End stage renal disease (ESRD) is irreversible and mostly develops over a period of 
time. It is caused by chronic primary or hereditary kidney diseases like chronic 
glomerulonephritis, chronic tubulo-interstitial nephritis, polycystic kidney disease, 
diabetic nephropathy. In most cases it is treated intermittently in special dialysis centers 
of hospitals or at home. Many patients survive on dialysis for as much as 30 years. 
 
2.2.1 Acute renal failure (ARF) 
 
Acute renal failure (ARF) is a rapid loss of renal function due to damage to the kidneys, 
resulting in retention of nitrogenous (urea and creatinine) and non-nitrogenous waste 
products that are normally excreted by the kidney. Depending on the severity and 
duration of the renal dysfunction, this accumulation is accompanied by a number of 
metabolic disturbances, such as anemia, metabolic acidosis (acidification of the blood), 
hyperkalaemia (elevated potassium levels) and changes in body fluid balance, which 
affects many other organ systems. It can be characterized by oliguria or anuria (decrease 
or cessation of urine production). 
Pathogenesis of ARF is multifactorial. According to the place of renal damage ARF can 
be categorized as pre-renal, intra-renal and post-renal causes. Pre-renal ARF normally 
initiates from the problems in blood supply like shock. Intra-renal ones are usually due 
to damage of the glomerulum or the tubule while post-renal ARF is caused by the 
obstruction in the urinary tract e.g. by tumor, kidney stones or infection.  
Nevertheless, ARF is caused by a disease outside the kidney, which also has to be 
treated. A high number of ARF patients suffer from sepsis, which is a general infection 
of the whole body. Therefore not only normal excretory function has to be replaced but 
also additional endogenous or exogenous nephrotoxic substances have to be removed. 
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2.2.2 End stage renal disease (ESRD) 
 
Chronic renal failure (CRF) is characterized by progressive and irreversible nephron 
loss such that glomerular filtration rate (GFR) is substantially reduced below normal. 
There are five stages of reduced kidney function in CRF according to endogenous 
clearance of creatinine [106]. In the case of stage 5, which is termed “End stage of renal 
disease” (ESRD), regular disalysis treatment is required for the patients. 
 
Stage  Description  GFR ml/min pro 1.73 m2 
1  Normal kidney function ≥     90 
2  Mild damaged kidney function 60 ~ 89 
3  Moderately damaged kidney function 30 ~ 59 
4  Massive damaged kidney function 15 ~ 29 
5  Renal failure, dialysis required <      15 
 
Table 1: Stages of renal failure [106]. GFR: glomerular filtration rate in 
terms of creatinine clearance; GFR below 10 ml/min is an absolute 
indication for initiation of regular renal replacement therapy. 
 
2.2.3 Non-renal failure 
 
There are a number of diseases where blood purification by extracorporeal devices is 
indicated like in acute poisoning, familial hyperlipidemia, sepsis and other immunologic 
diseases, where substances, which can not be sufficiently removed by the natural kidney 
have to be removed from blood. 
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2.3 Principles of extracorporeal blood purification systems 
 
The main driving forces of extracorporeal blood purification are concentration 
dependent diffusion, pressure dependent filtration and absorption. Since in these kinds 
of therapy vital substances are also separated from the blood, substitution of such 
solutes like electrolytes and buffer anions is necessary. Mass exchange in extracorporeal 
blood purification is performed in a hemofilter, hemodialyzer, plasmaseparator or in an 
absorption cartridge. 
 
2.3.1 Hemodialysis (HD) 
 
 
Figure 2: Principle of hemodialysis [77]. UF: Ultrafiltration fluid, RF: 
Replacement fluid. 
 
Hemodialysis is a process whereby the solute composition of blood is altered by 
diffusion along a concentration gradient across a semipermeable membrane. It was first 
performed in clinical practice by Haas in 1924 [45]. Mass exchange is performed in the 
hemodialyzer. The membrane, which can be constructed as a coil, flat sheet or hollow 
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fibre device, is part of the hemodialyzer. Today more than 95% are hollow fibre 
dialyzers [29]. The membrane area of the hemodialyzer is 0.3 to 2.6 m2 [126]. The inner 
diameter of the hollow fibres is 180 ~ 240 µm. The length of the hollow fibres is 15 ~ 
26 cm. Depending on the molecular cut-off of the membrane so called low-flux 
(molecular cut-off at about MW 1000) and high-flux (molecular cut-off at about MW 
60 000) membranes are used. The dialyzer is perfused in an extracorporeal circuit on 
one side of the membrane with the blood of the patient at a rate of 200 to around 400 
ml/min. On the other side of the membrane the dialyzer is perfused in a countercurrent 
mode with the dialysing fluid at a rate of 500 ml/min. The dialysing fluid contains 
sodium, potassium, calcium, magnesium, chloride, glucose and bicarbonate in 
approximately physiological concentrations. 
The hemodialysis procedure is controlled by the dialysis machine, which comprises the 
extracorporeal blood-circuit, the dialyzer and preparation and handling of the dialysing 
fluid. Monitoring of the extracorporeal circuit includes the blood pump, arterial and 
venous pressure control, blood-leak and air detection and continuous heparinization. 
The dialysing fluid is prepared continuously from deionized water and salt concentrates 
in adequate proportions. Thereafter it is heated and degassed. Its chemical composition 
is controlled by continuous conductivity measurement. There are several devices for 
control of ultra-filtration.  
In hemodialysis therapy only a small amount of filtration is necessary (0.5 ~ 4.0 l within 
4 hrs) to remove the excess ingested fluid from the patient. More than 95% of patients 
with end stage renal failure are treated with intermittent hemodialysis. Using dialysis 
monitors with fluid balance control, hemodialyzers as well as hemofilters can be used. 
 
2.3.2 Hemofiltration (HF) 
 
In hemofiltration (HF) solutes are removed exclusively by convective transport using a 
hemofilter imitating the filtration process in the glomerulum of the natural kidneys. 
Depending on the TMP, all solutes pass the filter within the limits of the membrane 
pore size with nearly the same concentration as in the blood and only depending on their 
sieving coefficients (SC). 
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Figure 3: Principle of hemofiltration [77]. UF: Ultrafiltration fluid. 
 
The membrane area of the hemofilter applied in hemofiltration is 0.3 to 2.4 m2 [126]. 
The membranes are so called high-flux membranes. Ultrafiltrate volume has to be fully 
replenished by a replacement fluid or substitution fluid.  The composition of the 
replacement fluid is similar to that of the dialysing fluid used in hemodialysis. The 
replacement fluid can be substituted before or after the hemofilter (pre- / post-dilution 
mode). The first hemofiltration to treat patients with highly permeable membranes was 
accomplished by Henderson and Bluemle in 1967 [51]. Like in hemodialysis, HF is 
controlled by a machine monitoring the extracorporeal blood circuit and the 
simultaneous exchange and balance of filtrate and substitution fluid. In intermittent HF, 
within 4 hours of treatment a volume of 20 ~ 25 l of ultrafiltrate is removed from the 
patient and part of it replaced by about 20 l of substitution fluid.  
HF clears blood from solutes of a higher molecular weight spectrum including very low 
concentrated uremic toxins that may be responsible for severe uremic symptoms. HF 
seems to provide better protection of the cardiovascular system against the fluctuations 
in extracellular volume [12, 94]. Only about 5% of ESRD patients are treated by 
intermittent hemofiltration. 
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2.3.3 Hemodiafiltration (HDF) 
 
 
Figure 4: Principle of hemodiafiltration [77]. UF: Ultrafiltration fluid, RF: 
Replacement fluid. 
 
Hemodiafiltration (HDF) combines the low-molecular-weight solute clearances 
achieved in HD by diffusive solute transport and the relatively high clearances of the 
larger uremic toxins (so-called middle molecules: MM) as achieved with HF by 
convective solute transport. Therefore HDF provides considerable advantages over both 
HD and HF in which small and large solutes are removed efficiently [140]. This 
dialytic technique was introduced by Leber in 1978 [72].The membrane area of the 
hemofilter is 0.2 to 2.5 m2 [126]. 
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2.3.4 Peritoneal dialysis (PD) 
 
 
 
 
Figure 5: Components of peritoneal dialysis [77]. 1. peritoneal cavity, 2. 
catheter, 3. catheter with titan adapter, 4. valve gear, 5. Y-branch, 6. clamp, 
7. dialysing fluid bag, 8. dialysate collecting bag. 
 
Peritoneal dialysis (PD) is a kidney replacement therapy where the natural peritoneum 
of the patient acts as semi-permeable membrane barrier. For this purpose the peritoneal 
cavity of the patient is drained via a catheter with the dialysing fluid. After solute 
exchange with the blood of the patient across the peritoneal membrane the toxin 
containing dialysate is removed and then replaced with new dialysing fluid. 
Composition of the dialysing fluid is similar to hemodialysis fluid with additional high 
glucose concentration in order to remove water by an osmotic driving force. PD was 
first described by Ganter in 1923 [37]. Like hemodialysis, mass exchange is 
predominantly via diffusion. PD can be performed intermittently or continuously. Since 
application of an indwelling permanent catheter in 1965 by Tenckhoff [118], long-term 
continuous PD has become possible. At present 5% of patients with ESRD are treated 
with continuous ambulatory peritoneal dialysis (CAPD) using about 10 l of dialysing 
fluid per day.  The surface area of the adult peritoneum has been measured between 
0.55 and 2.07 m2 [19, 57, 103]. The molecular cut-off of this natural membrane is 
somewhat higher to that of the glomerular membrane. The clinical advantage of CAPD 
versus intermittent hemodialysis is its smooth continuous mass exchange and no 
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requirement of anticoagulation. Peritonitis and deterioration of fluid and solute 
permeability of the peritoneal membrane are the main clinical problems for chronic PD 
patients. 
 
2.3.5 Hemoperfusion 
 
Hemoperfusion is a blood purification method accomplished by sorbent particles 
contained in a plastic housing (adsorption cartridge), which is connected to the 
extracorporeal circuit. This concept was first applied by Muirhead and Reid in 1948 to 
remove the uremic toxins from animals [86].  
This method is used for the treatment of drug and chemical poisoning. The 
extracorporeal circuit used for hemoperfusion is similar to dialysis. Heparin or citrate is 
necessary for blood anticoagulation. Typical sorbents are activated carbon, ion 
exchange resins and non-ionic macroporous resins. During hemoperfusion, blood 
directly contacts with sorbents. High blood compatibility of sorbents is vital, as well as 
freedom from microparticles, toxicity and pyrogenicity [43]. Due to its high porosity, 
absorptive sorbents have large surface area and extremely high absorptive capacity 
depending on the materials used. Activated carbon has the approximate surface area of 
1,000 m2 /g, while resins have the surface area of 300 to 500 m2 /g. The amount of 
sorbents in each device from different manufacturers varies from 50 g to 350g [57].  
 
 
2.3.6 Plasmaseparation 
 
Plasmaseparation (plasmapheresis, apheresis) is the process of removal, selective 
treatment and return of plasma from blood containing substances having pathogenic 
effects. The high molecular weight substances to be removed are lipids, 
immunoglobulins or protein-bound toxins. The separation process can be operated by 
cascade filtration using a plasmafilter, immunoprecipitation, absorption or 
cryoprecipitation [57].  
Plasmaseparation procedures are used to treat a variety of disorders like familial 
hypercholesterolemia including those of the immune system, such as Guillain-Barré 
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syndrome, lupus and thrombotic thrombocytopenic purpura. It was first used by 
Rubinstein to treat immune-related disorders in 1959 [137]. 
During plasmapheresis, blood is taken out of the body through a vein or an arterio-
venous fistula. Plasma is then separated from the blood either by continuous or 
discontinuous flow centrifugation or by continuous plasma filtration using a high cut-off 
plasmafilter [30]. In order to eliminate plasma proteins, immunoglobulins and 
lipoproteins which normally are not eliminated by the kidneys, it is necessary to use 
plasmafilters with molecular cut-off around MW 1000 000 [73].  
At present hollow-fibre filters or absorption devices are commonly used for plasma 
filtration. Because of cellular concentration polarization and increase of hematocrit, 
hollow-fibre filters can only be operated at a maximum filtration fraction of 0.3. Flat 
sheet devices offer the advantage of higher filtration fraction than hollow fibres up to 
0.6 [43].  
 
2.4 Toxins to be removed in artificial blood purification 
 
In acute or chronic renal failure, the uremic retention solutes, which have to be removed 
from the blood of the patients are commonly referred to as uremic toxins. They include 
metabolic waste products like urea, creatinine and uric acid. These substances have a 
low molecular weight between MW 60 and MW 186, are of relatively high molar 
concentration and of relatively low toxicity. They are continuously generated by 
metabolism of protein. There are also many toxic substances at much lower molar 
concentration and having higher molecular weight. Because of their molecular weight 
between MW 500 and MW 40 000, which is the molecular cut-off of the glomerular 
membrane, they are termed “middle molecules (MM)” [5]. The specific toxicity of most 
MM is unknown. However, experimental evidence shows that these substances play an 
important role in the pathogenisis of renal failure and its consequences [134]. Because 
of their very low molar concentration these substances are generally more efficiently 
removed from blood via convection than via diffusion. 
In some primarily non-renal diseases substances have to be removed which normally are 
not eliminated by the kidneys. These substances have higher molecular weight than the 
cut-off of the glomerular membrane and include lipoproteins, protein-bound 
endogenous and exogenous toxins and antibodies in certain specific clinical diseases 
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like autoimmune diseases. These substances can only be removed by apheresis or 
hemoperfusion. 
Small, middle and large molecular weight uremic toxins have been studied and 
arbitrarily classified by the “European Uremic Toxin Work Group” [134]. 
Solutes of MW < 500 fall into the small molecules,  
500 < solutes of MW < 40 000 are defined as middle molecules here. 
Compounds of MW larger than 65 000 are regarded as large molecules. Table 2 
summaries the key properties of some of the most widely studied uremic toxins. 
 
Low-molecular-weight toxins 
Solute MW CN (mmol/l) CU (mmol/l) CMax  (mmol/l) 
Urea 60   <6.7  38.3    76.7 
Oxalate 90  3.33×10-3    0.05      0.08 
Creatinine 113   <0.11    1.20      2.12 
β-guanidinopropionic acid 131   <2.5 × 10-5    2.2 × 10-4      5.0 × 10-4 
α-keto-δ-guanidinovaleric 
acid 
151   <2.0 × 10-4    n.a.      9.3 × 10-4 
Uric acid 168   <0.4    0.50      0.87 
Guanidonosuccinic acid 175 1.7 × 10-4    0.04      0.27 
1-methylinosine 179   <2.8 × 10-5 1.4 × 10-3 2.6 × 10-3 
Xanthosine 284 8.4 × 10-5 3.4 × 10-4 7.8 × 10-4 
N2, N2-dimethylguanosine 311     2.9 × 10-5 7.6 × 10-4 1.3 × 10-3 
Middle-molecular-weight toxins 
Solute MW CN (mmol/l) CU (mmol/l) CMax  (mmol/l) 
Neuropeptide Y 4 272 < 1.9 × 10-8 1.5 × 10-8 2.7 × 10-8 
β2 microglobulin 11 818 < 1.7 × 10-4 4.7 × 10-3 8.5 × 10-3 
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Cystatin 13 300 < 1.2 × 10-4 8.9 × 10-4 1.5 × 10-3 
Interleukin-6 24 500  5.4 × 10-10 3.8 × 10-9 1.3 × 10-8 
κ-Ig light chain 25 000  1.4 × 10-3 2.8 × 10-3      0.011 
Tumor necrosis factor-α 26 000  5.1 × 10-10 4.4 × 10-9 1.6 × 10-8 
Interleukin-1β 32 000 < 5.0 × 10-9 1.3 × 10-8 5.3 × 10-8 
Protein-bound toxins 
Solute MW CN (mmol/l) CU (mmol/l) CMax  (mmol/l) 
Methylglyoxal 72     6.5× 10-4 1.5 × 10-3     2.0 × 10-3 
Putrescine 88     2.4× 10-4 8.8 × 10-4     1.5 × 10-3 
p-cresol 108     5.6× 10-3    0.19       0.38 
Homocysteine 135   <0.01    0.06       0.20 
Hippuric acid 179   <0.03    1.38       2.63 
Indoxyl sulfate 251     2.4× 10-3    0.21       0.94 
Pentosidine 342     1.5× 10-4 2.6 × 10-3  8.7 × 10-3 
Leptin 16 000     5.3× 10-7 4.5 × 10-6  3.1 × 10-5 
 
Table 2: Review of uremic toxins (converted from [134]). CN: normal 
plasma concentration, CU: mean plasma concentration in anuric patients, 
CMax: maximal plasma concentration in anuric patients. 
 
2.5 Membranes and filters 
 
The medical device by which blood is cleaned is the artificial blood-filter. Depending 
on the mode of treatment it is called hemodialyzer, hemofilter or plasmafilter. Each 
blood filter contains an artificial membrane, which separates blood from dialysing fluid 
or filtrate. 
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2.5.1 Membranes for blood purification 
 
Since the first cellulosic dialysis membrane which has been used in 1913 by Abel and 
Rowntree [2] there were many developments on  membrane polymers and membrane 
geometry.   
There are three types of membranes currently used in hemodialysers and hemofilters: 
cellulose, modified cellulose and synthetics.  
Cellulose: It is obtained from processed cotton. Cuprophan® once was the most 
common type of hemodialyzer membrane until 1990. Cellulosic membranes are also 
called regenerated cellulose: the membranes are hydrophilic and have low-flux 
permeability. 
Modified cellulose: Cellulose polymer is a straight chain polymer having a large 
number of free hydroxyl groups on the glucose units. In the cellulose acetate membrane, 
varying number of these acetate groups are used to substitute OH group. In the modified 
cellulose (Hemophan®) membrane, some of the surface hydroxyl groups are chemically 
replaced by a tertiary amino compound. 
Synthetic: The synthetic membranes used in hemodialysis therapy are made from 
different polymers like polyacrylonitrile (PAN), polyamide (PA), polysulfone (PSu) 
and polymethylmethacrylate (PMMA). The main purpose of developing synthetic 
membranes was to create more porous membranes which can better simulate the 
filtration process of the natural kidney thereby removing higher molecular weight 
uremic toxins so-called such as β2 microglobulin (β2 M) [127].  
Dialysis membranes may be either symmetric (almost all cellulosic membranes, 
PMMA, PAN and AN69ST®) or asymmetric (PA and PSu). Asymmetric structures 
have a thin inner separation layer on the blood side that essentially determines the 
sieving properties of the membrane, and at least one support layer that provides 
mechanical strength in order to withstand TMP. The size and morphology of this 
support layer varies considerably from membrane to membrane. For high-flux 
membranes such as PA or polyarylethersulfone, the support layer is characteristically 
either a finger type or macrovoid structure. Membranes like the Fresenius Polysulfone® 
have a sponge-like structure, gradually increasing in porosity from blood side to 
dialysing fluid side. 
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The polymer chemistry and structure essentially determines the biological and physical 
behavior of a dialysis membrane. Physical differences also exist between cellulosic and 
synthetic membranes. Cellulosic membranes must be made relatively thin (wall 
thickness of dry fibre in the range of 6.5 to 15 μm) in order to achieve high diffusive 
solute transport and have a uniform (symmetric) structure of the fibre wall. Such 
membrane structure cannot sustain the high TMP necessary in convective dialysis 
treatments such as HF or HDF [127]. 
Synthetic membranes are thicker (>20 μm) and may be either symmetric or asymmetric. 
They permit high water permeability to allow use in hemofiltration. An asymmetric 
structure implies a thin blood-contacting ‘skin’ layer (approximately 1 μm) and a 
support layer that includes the rest of wall thickness. The pore structure of this support 
layer, which varies considerably among the various synthetic membranes [39, 101] is 
much more open than the skin layer and has little influence on the trans-membrane 
solute removal capability. For example, pore diameter of PMMA membrane varying 
between 2 to 10 nm [116]. 
 
 
 
     
 
 
   
 
Figure 6: Different membrane structure depending on the type of polymer 
and used for the production (adapted from [128]): Cellulose (left); 
Polysulfone (middle); polyamide (right). 
 
The surface charge is another important feature of membranes and influences solute 
transport across the membrane. Zeta potential is used to describe the electrical charge on 
the membrane. It is the charge that develops at the interface between a solid surface and 
its liquid medium. The zeta potential indicates the degree of repulsion between adjacent 
charged particles in its contacting medium (e.g. blood) and the membrane. Most 
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cellulosic membranes are negatively charged. Synthetic membranes can be also 
catalogned according to their negative charge in the order: AN69® (-89 mV) > PAN DX 
(-85 mV) > SPAN (-70 mV) > PMMA (-25mV) > PSu (-2.5 mV), the others are mostly 
neutral [95].  
 
2.5.2  Membrane biocompatibility 
 
Interactions between blood and the artificial surface of the membrane are the cause of 
unwanted side-effects during renal replacement therapy. Biocompatibility has been 
defined as the ability of a material or device or system to perform without a clinically 
significant host response [44]. Different biological systems are activated during blood-
material interaction. 
a. Thrombogenicity  
Surface free energy, charge, roughness and chemical composition of the membrane 
have been identified as being responsible for the variable thrombogenic potential of 
hemodialyzer membranes [122]. Membranes with electronegative surfaces (such as 
PMMA, AN69®) can activate the clotting cascade and are more thrombogenic than 
neutral ones. These differences between membrane materials can be proved by the 
assessment of high molecular weight kininogen form eluates and thrombin-antithrombin 
III complex (TAT) level in the blood [27, 87]. 
In contrast to coagulation factors, platelet adhesion and activation takes place more 
frequently on the cationic charged and hydrophobic surface of membranes [83]. Platelet 
activation is highly expressed with Cuprophan® and lowest with AN69® [18]. 
b. Complement activation 
Complement activation usually works in two pathways: the classic and alternative 
pathway [138]. Cellulosic membranes have been found to be the strongest complement 
activators of all hemodialyzer membranes because of free hydroxyl groups in the 
cellulose structure. The free hydroxyl groups can bind C3b through the alternative 
pathway. The parameters mostly used for assessment of complement activation by 
hemodialysis membranes are the formation of C3 and C5 active fragments. 
c. White cell activation 
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Leukopenia is phenomenon, which usually occurs 15 to 30 minutes after starting 
hemodialysis therapy when blood flows through the hemofilter. Leucocyte 
concentrations drop down to as low as 20% of the initial amount. Thereafter leukocyte 
level returns to normal till the end of one treatment session. Again cellulosic 
membranes cause strongest leucopenia due to the increased adhesiveness of leukocytes 
to the membrane. Protein oxidation products and induction of cytokine generation are 
used to measure the reactions of patients’ body to specific membranes. Leucopenia also 
may be induced by contaminated dialysing fluid [92, 109, 113]. 
d. Activation of the kinin system 
Negatively charged dialysis membranes can activate the kinin-system and cause 
anaphylactoid reactions [120]. These reactions are symptomatic blood pressure drop and 
paresthesia in the extremities due to peripheral vasodilatation, which might happen as 
soon as blood flow contacts with the membrane of the hemodialyzer. The main cascade 
is that positive charged factor XII adheres onto the negative charged surface of the 
membrane and produces factor XIIa, which can activate pre-kallikrein to kallikrein. 
Consequently kallikrein is able to activate more Factor XII and cleaves high molecular 
weight kininogen and release bradykinin.  
Bradykinin is a tissue hormone with a variety of local effects, e.g. intestinal motility, 
vasodilatation or vasoconstriction, bronchoconstriction and stimulation of glucose 
uptake by prostaglandin and histamine [38]. Anaphylactoid reaction during 
hemodialysis caused by generation of bradykinin is enhanced by angiotensin converting 
enzyme  (ACE) inhibitors [120] given to the patients in order to treat arterial 
hypertension. In order to overcome the problems with anaphylactoid reactions, the 
AN69® membrane has been modified by coating the membrane with a polycationic 
polymer (polyethylene-imine: PEI) for AN69ST®. This negative zeta potential of the 
AN69 ST (ST: surface treated) is diminished from -70 ± 10 mV to -15 ± 5 mV [75, 96]. 
 
2.5.3 Artificial blood filters 
 
The device containing the separating membrane in the extracorporeal circuit is called 
hemodialyzer, hemofilter or plasmaseparator. These blood filters contain a blood 
compartment as well as dialysate or filtrate compartment. In order to reduce the 
extracorporeal blood volume, the blood compartment has been minimized. This is best 
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obtained using hollow-fibre membranes. The blood compartment volume in filters with 
hollow-fibres can be as small as 16 ml for infants and goes up to 160 ml for filters for 
adults [126].  
Three different types of blood filters can be distinguished: coil, flat plate and hollow 
fiber devices. The first successful hemodialyzer was constructed by Kolff and Berk in 
the Netherlands in 1943 [67]. A cellophane (cellulose) tube formed the dialysis 
membrane and the tube was wound around a rotating drum immersed in a bath of saline. 
Kolff’s first tubular hemofilter required several liters of blood to prime the system. In 
1950s tubular hemofilters were replaced with coil (spiral) devices, also developed by 
Kolff and Watschinger [68]. This coil system was the basis for the first disposable 
hemofilters produced commercially in the early 1960s. The blood volume required to 
prime the device was still excessive. During 1960s, the plate-and-frame and hollow 
fiber devices were developed. In 1975, about 65% of all hemofilters were coil, 20% 
from hollow fibre system and 15% from plate-and-frame in the USA. Within 10 years 
the coil hemofilter essentially disappeared and the market was divided two-third into 
hollow fibres and one-third into plate-and-frame. By 1996 hemofilters of hollow-fibre 
took more than 95% of the market. Today over 90 million hemodialyzers are produced 
every year [102]. 
   
 
Figure 7: Different types of hemofilters (A: coil, B: flat plate, C: hollow 
fibre) [128]. 
 
Depending on the size, the hollow fibre dialyzer consists of a bundle of approximately 7 
000 to 14 000 fibres [21] encased in a plastic housing and potted at both ends in 
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polyurethane (PU) sealing materials. It has a cylindrical polycarbonate cartridge with 4 
openings. The hollow fibre bundle, encased in the housing, has a blood inlet and a blood 
outlet port. This forms the blood compartment of the dialyzer. Two other ports are cut 
into the side of the cylinder. They communicate with the space around the hollow fibre, 
the dialysate compartment. Blood is pumped via the blood port through this bundle of 
capillary-like hollow fibres, and the dialysing fluid is pumped through the space 
surrounding the fibers in a countercurrent direction to blood flow. Pressure gradients are 
applied when necessary in order to remove fluid from the blood of the patient. Surface 
area of these dialyzers ranges from approximately 0.4 to 2.5 m2, length is 20 ~ 26 cm.  
The inner diameter of hollow-fibres for hemodialysis ranges from 175 to 240 μm, most 
being 200 μm. The volume of the blood-compartment used in adults, ranges from 16 ml 
to 160 ml [126]. 
 
2.5.4  Testing of membranes and hemofilters  
 
As a medical device, the essential properties of membranes and hemofilters have to be 
examined in order to apply it to specific medical indications. 
 
2.5.4.1 Testing membranes 
 
The most important properties of membranes for blood purification therapy are 
hydraulic and solute permeability. They are generally tested in-vitro or in-vivo. 
Hydraulic permeability (Lh) of the membrane is defined as the volumetric flow rate per 
unit of area per unit of pressure gradient (ml/(min·m2·mmHg)). Hydraulic permeability 
of membranes for extracorporeal blood purification ranges from 2.9 to 53 
ml/(h·m2·mmHg) [22]. It depends on the membrane porosity (ρ), which is a function of 
pore number, pore size and pore size distribution [22]. 
    ρ = N π r2                                               (Eq. 2) 
      N: number of cylindrical pores (per unit membrane surface area) 
      r : radius of pore 
Solute permeability of membranes can be measured by the sieving coefficient (SC) of a 
substance in aqueous solution or in blood. 
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SC is defined as the ratio of the solute concentration in the ultrafiltrate (Cf) to that in the 
primary solution (Ci) [14]: 
      SC = Cf / Ci                                                               (Eq. 3) 
SC = 1 means that the particular solute can transfer across the membrane freely.  A 
value SC = 0 means that the membrane is impermeable for this particular substance. 
The SC of urea, creatinine, Vit B12 and ß2 microglobulin are available in the most 
datasheets of hemofilters. 
 
2.5.4.2 Testing hemofilters 
 
The performance of hemofilters is generally defined in terms of four aspects:  
(a)  Ability to produce a filtrate.  
(b)  Ability to remove low molecular weight waste products like urea and  
       creatinine (small solute clearance). 
(c)  Ability to remove middle molecules (middle molecule clearance).                                                 
(d)  Ability to retain albumin and larger molecules [128]. 
The ultrafiltration coefficient (UFcoeff) is used to characterize the water permeability of 
the hemofilter. Hemofilters are different with regard to membrane porosity and surface 
area (A). On the basis of hydraulic permeability (Lh) of the membrane, UFcoeff is 
calculated as the product of hydraulic permeability of the membrane and surface area   
in the dialyzer:  
UFcoeff = Lh • A       ml/ (h·mmHg)                     (Eq. 4) 
UFcoeff of a hemodialyzer is usually derived from in vitro experiments at varying TMP.  
Ultrafiltration rate (UFR) can be computed by the product of UFcoeff and TMP, which is 
the pressure gradient between the two sides of membrane, i.e.  
UFR = UFcoeff   • TMP      ml/h                       (Eq. 5) 
Higher UFR allows greater contribution of convection to solute removal and better 
removal of larger solutes. In vivo, UFcoeff of a hemodialyzer can differ from the 
published in-vitro values because of varying haematocrit protein content and protein 
adsorption on membrane surface. Therefore, variation of up to ± 20% is observed [128]. 
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In all hemodialysers the relationship between plasma water ultrafiltration and TMP is 
linear.  
Solute transport through a hemofilter is expressed by clearance (K). The clearance of a 
hemofilter for a certain substance is defined as the amount of solute removed from the 
blood per unit time, divided by the incoming blood concentration [14]. Solute transport 
of a hemofilter is dependent on the surface area and the porosity of the membrane, flow 
of blood and dialysing fluid, filtration rate and the molecular weight of the solute. 
Clearance for hemodialysis can be calculated by the following equations:  
Hemodialysis (blood):  
 K = Qbi (Cbi-Cbo)/Cbi + UFR (Cbo/C bi) ml/min            (Eq. 6) 
Hemodialysis (dialysate):  
K = Qdi (Cdo-Cdi)/Cbi + UFR (Cdo/Cbi) ml/min              (Eq. 7) 
 
Qbi: inlet blood flow rate, Cbi: inlet concentration in plasma water, Cbo: outlet 
concentration in plasma water; Cdi: inlet concentration in dialysing fluid; Cdo: outlet 
concentration in dialysate, Qdi: inlet flow rate of dialysing fluid, UFR: 
ultrafiltration rate 
The first parts of both equations represent solute clearance by diffusion, while 
secondary parts shows the solute clearance by convection, which can be cut in the 
absence of ultrafiltrate flow. The larger the solute or the lower its concentration the 
more convection contributes to its removal. 
Hemofiltration:  
K = (UFR • Cf) /Cbi  ml/min                     (Eq. 8) 
UFR: ultrafiltration rate, Cf: concentration in filtrate, Cbi: inlet concentration in plasma 
water    
Dialyzer clearances measured in-vitro are generally higher than those measured using 
blood, because only a fraction of the blood (plasma water) is available for solute 
removal, as cells and plasma proteins in the blood occupy space. The distribution space 
of solutes in whole blood is compartmentalized for intracellular space, extracellular 
fluid and plasma water. Reduced clearances partly depend on the diffusion rates of these 
 23
solutes between different compartments. The reduced clearance in-vivo can also be 
caused by influences of blood access and cardiopulmonary recirculation [128]. As 
diffusion rate of solutes is inversely proportional to the square root of the solute 
molecular weight [25, 58], diffusive clearances of solutes larger than MW 1000  are 
normally clinically irrelevant. 
 
2.6 Kinetics of solute removal in blood purification 
 
When treating a patient using artificial blood purification systems removal of solutes 
not only depends on the properties of the membrane and of the hemofilter, the mode of 
treatment (hemodialysis, hemofiltration) and the time and frequency of application but 
also on the generation rate of a solute in the body of the patient. It has to be taken into 
consideration that the human body itself can be divided into several fluid compartments, 
which are separated by membranes. The most important fluid compartments of the 
human body are the intracellular space, the extracellular space and the intravascular 
space. These compartments are separated by the cellular membrane and the capillary 
membrane of the blood vessels. The solutes are not evenly distributed in those 
compartments, e.g. urea is proportionately distributed in the extracellular and the 
intracellular compartment whereas ß2 microglobulin is only distributed in the 
extracellular compartment and urea has a very high mass transfer coefficient through the 
membranes of the human body whereas ß2 microglobulin has a very low masstransfer 
coefficient. Therefore, solute removal in blood cleansing also depends on the chemical 
properties of a specific solute, its generation rate and mass transfer coefficient between 
the internal fluid compartments. In addition there is a fat compartment of the body 
indicating that body weight only with some constraint can be used as a measure of body 
water content. 
Therefore the amount or dose of blood purification therapy can only be estimated when 
considering the kinetics of mass transfer from the generation of toxins to be removed by 
their permeation through the compartments of the human body and the efficiency of 
blood purification therapy. Existing mathematical models calculate kinetics of urea, 
sodium and ß2 microglobulin [1, 42, 114]. 
A first step approach to kinetics of solute removal in intermittent therapy is given by the 
pre- to post- dialysis percentage reduction (PR).  Disregarding the endogenous 
generation rate of the solute during treatment, the following equation can be applied: 
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PR = [(Cpre-Cpost)/Cpre] • 100%               (Eq. 9) 
Cpre: concentration of solute before treatment, Cpost: concentration of solute after 
treatment 
As an approximate value often urea reduction ratio (URR) is used to evaluate efficiency 
of intermittent blood purification therapy. More sophisticated mathematical models [41, 
81] and approximation formulae [28] are used to calculate Kt/V as the dose of 
intermittent hemodialysis, where K is the clearance of urea, t the duration of dialysis 
therapy and V the urea distribution volume in the body of the patient. Kt/V describes 
the exponential decrease of urea concentration during one dialysis session. Kt/V = 1.2 is 
generally accepted as an adequate dose of three-times-per-week intermittent 
maintenance hemodialysis therapy [49, 81]. Because of continuous and simultaneous 
removal and generation of urea PR and URR and Kt/V cannot be applied in CHF. In 
CHF like in the natural kidney, dose of therapy is given by the clearance of one solute 
per day or per week. 
Effects of different doses of ultrafiltration in CHF were assumed to influence the 
survival outcome of critical ill patients. Higher ultrafiltration dose has better survival 
rate by treating those patients. Dose of ultrafiltration can be calculated by ultrafiltration 
rate divided by the body weight of patient (ml/h•Kg). 
 
2.7 Continuous renal replacement therapy (CRRT) 
 
Continuous extracorporeal blood purification is performed exclusively to treat acute 
conditions and diseases of patients in intensive care units (ICU). In these patients not 
only replacement of excretory renal function but also sometimes elimination of 
cytokines and other high molecular weight substances and protein bound toxins is 
indicated. Since these patients often suffer from low blood pressure, continuous blood 
purification therapy with reduced mass exchange of low molecular weight solutes is 
considered to be more convenient than intermittent therapy [8, 9, 63]. Thus CRRT can 
be used accordingly as a “bridge” until the patient can tolerate conventional 
hemodialysis, or, excretory function of the kidneys recovers. CRRT is estimated as a 
safe and effective method to treat volume overload and to replace renal function in 
critically ill patients [47].   
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2.7.1 Indications 
 
The main indication of CRRT is acute renal failure secondary to acute intoxication and 
septic or non-septic shock syndrome. The systemic inflammatory response syndrome 
(SIRS) is defined as an inflammatory reaction to any one of a number of insults 
including infection, burns, and trauma. It is evident with at least two of the following 
clinical symptoms: (1) temperature greater than 38 °C or less than 36 °C; (2) heart rate 
greater than 90 beats per minute; (3) tachypnea, defined as respiratory rate greater than 
20 breaths per minute or hyperventilation with an arterial carbon dioxide pressure 
(PCO2) less than 32 mm Hg; and (4) alteration of leukocyte count to greater than 12 000 
cells/mm3, less than 4 000 cells/mm3, or greater than 10% immature neutrophils. Sepsis 
is defined as SIRS caused by infection, it can further turn into severe sepsis when the 
illness is complicated by organ dysfunction, hypoperfusion abnormality (lact acidosis, 
oliguria, or mental status changes) and hypotension. The septic shock is sepsis 
associated with hypotension, which is not responsive to fluid volume recovery. 
Development of severe sepsis is mainly caused by the host inflammatory response. In 
the host, bacterial products trigger defense mechanisms mediated by the release of 
cytokines and other circulating substances, the activation of plasma factors such as the 
complement and coagulation cascades, and the recruitment of cellular components. 
These responses may stop or remove microbial invasion and disease but may also cause 
significant damage to host tissue. Lipopolysaccharides (LPS) are endotoxins, which are 
the most important activator of host defense. It can induce release of pro-inflammatory 
cytokines including tumor necrosis factor alpha (TNF-α), interleukin-1 (IL-1), 
interleukin 6 (IL-6), interleukin 8 (IL-8) and interferon gamma (IFN-γ). IL-4, IL-10 
and IL-13 are recognized as anti-inflammatory cytokines and produced to down-
regulate the immune response [105]. 
The concept of effective cytokine removal by CRRT has been the subject of 
controversy since CRRT was introduced [33]. It has been found that septic patients 
have a high production rate and a high endogenous clearance of pro-inflammatory 
cytokines. Those cytokines have a short plasma half-time of 6 ~ 20 min [13, 47].  
Because it has been shown that sepsis plays an important role in the onset of ARF [59] 
and combination of sepsis shock and ARF accounts for as high as 75% of the mortality 
of patients [17, 60], CRRT is often used with the concept of modulating immune 
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response in the beginning of SIRS [88]. Early initiation and higher doses of CRRT 
treatment can improve the survival rate significantly [16, 99]. 
 
2.7.2 Modes of treatment 
 
CRRT was first proposed by Kramer in 1977 in the mode of continuous arterio-venous 
hemofiltration (CAVH) [69]. In this therapy mode, blood is continuously heparinized 
and passes through the hemofilter and ultrafiltrate is collected in a plastic container. 
Different modes of CRRT have since been developed. 
 
Continuous arterio-venous hemofiltration (CAVH) 
In this kind of therapy blood flow is achieved by puncture of the femoral artery and 
arterial blood pressure of the patient. The hemofilter is connected using extracorporeal 
blood lines. There is continuous heparinization to prevent systemic thrombosis of the 
extracorporeal circuit.  The filtrate, which is produced spontaneously depending on the 
arterial blood pressure, is collected in a plastic bag. Fluid balance is performed by non-
simultaneous measurement of infusion rate and filtrate. The substitution fluid is similar 
to intermittent hemofiltration. The amount of filtrate is about 10 ~ 20 l/day [9, 100]. No 
further monitoring of the extracorporeal blood circuit is necessary. 
 
Continuous veno-venous hemofiltration (CVVH) 
Since in CAVH the daily rate of filtrate was variable and very often too low, 
continuous, pump-driven CRRT has been developed. Blood access may be arterial but 
in most cases is venous through a central venous catheter placed in one of the large 
central veins. The latter is termed continuous veno-venous hemofiltration (CVVH). 
Using this kind of blood access blood flow rates are usually in the range of 100 ~ 200 
ml/min. Operating with a blood pump requires some additional devices for control of 
the extracorporeal circuit like air detector, detectors of the arterial and venous blood 
pressure, and TMP, which nowadays are provided by a CRRT-monitor also 
simultaneously controlling fluid balance. Figure 8 shows the scheme of CVVH 
monitoring. 
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Figure 8: Circuit and monitoring of continuous veno-venous 
hemofiltration. 
 
CHF is normally applied for an extended period of time up to several weeks [100]. 
Substitution fluid can be either infused before the hemofilter (pre-dilution) or behind the 
hemofilter (post-dilution), or even in both dilution modes (pre & post-dilution). Using 
CVVH in the postdilution mode usually 20 ~ 40 l of daily ultrafiltrate are obtained [10, 
100]. High-volume hemofiltration (HVHF) has contributed to better survival rate in 
severe septic shock patients [26, 55, 99]. In HVHF daily ultrafiltrate can be as high as 
144 l/day. The infusion site of replacement fluid is pre-hemofilter (pre-dilution) [23]. 
 
Continuous hemodialysis (CHD)  
CHD is an extended period of hemodialysis using a dialysis monitor. It is executed 
through a veno-venous blood access. The prevalent mechanism of solute transport is 
diffusion. Ultrafiltration is only necessary to prevent fluid overload of the patients. In 
contrast to continuous filtration, low flux hemodialyzers can be used. 
 
Continuous hemodiafiltration (CHDF) 
CHDF combines the principles of hemodialysis and hemofiltration, similar to 
hemodiafiltration. Dialysing fluid is circuited in the hemofilter in counter-current mode 
to blood flow and ultrafiltration is carried out in the same way as hemofiltration. 
Optimal clearances are expected for solutes of both small and large MW. Filtration rates 
of 15 l/day ~ 40 l /day are obtained [100]. 
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2.7.3 Pre-dilution versus post-dilution 
 
In any kind of hemofiltration therapy replacement of water, electrolytes and glucose are 
required to maintain a physiological blood composition. This is done using a 
substitution fluid, which can be infused into the blood path either before the hemofilter 
(pre-dilution mode) or behind the hemofilter (post-dilution mode), or simultaneously in 
both ways (pre- & post-dilution mode) [50]. In pre-dilution mode, the blood is diluted 
before the hemofilter and no hemoconcentration occurs inside the hollow fibres whereas 
in the post-dilution mode there is considerable hemoconcentration at the end of the 
hollow fibres, which limits filtration rate. Because rheological conditions are generally 
better in the pre-dilution mode, frequent filter clotting is believed to be the main reason 
for the circuit interruption in the post-dilution mode [61, 107, 135]. Longer filter 
running time (FRT) was found in predilution mode [62, 125]. Since blood is diluted in 
the pre-dilution mode much more substitution fluid is needed to obtain an equivalent 
solute clearance like in post-dilution mode. By using the same amount of substitution 
fluid, post-dilution allows better clearances of small and middle molecules [20, 130]. 
 
2.7.4 Anticoagulation 
 
In any extracorporeal treatment the contact of blood with artificial surfaces (e.g. tubes, 
filter membrane) enhances procoagulatory activity depending on the materials of 
artificial surfaces thus inducing coagulation of blood [4, 128]. Filter clotting due to the 
blood coagulation is responsible for 40 ~ 75% of circuit interruptions and results in 
blood loss [107]. Therefore an anticoagulant has to be infused in individual doses into 
the patient’s blood in order to prevent activation of coagulation in all kinds of CRRT. 
Common anticoagulants are heparin and derivatives of low molecular weight heparin, 
hirudin, citrate and prostacyclin. Compared with intermittent hemodialysis, long-term 
administration of heparin may lead to potential disturbances of the hemostatic system. 
Regional anticoagulation of the extracorporeal circuit is only necessary in the case of 
internal or external bleeding of the patient [90]. 
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2.7.5 Filter running time 
 
Filter running time (FRT) is regarded as the time from beginning of the application of 
one hemofilter till spontaneous failure or loss of function so that the hemofilter has to be 
exchanged. There are several reasons for replacement of a hemofilter including visible 
clotting [61, 107, 124], decrease of UFR more than  50%, increase of  TMP required to 
achieve the preset UFR and insufficient blood flow [31, 85, 117, 130]. Unfortunately, 
there is no standardized definition for FRT until now [107]. Different physicians have 
their own hemofilter replacement criteria and have variable methods to assess the grade 
of membrane obstruction of the hemofilters in use. Planned interruption of CHF by 
surgery requirement or radial examination must be excluded in FRT recording. 
FRT ranges from 1 hour to about 10 days [34]. Different from intermittent treatment, 
throughout the whole hemofilter life time stable performance is urgently required to 
ensure quality of therapy [124]. Coagulation is considered as main factor that influences 
FRT. Catheter type, hemofilter properties (material, membrane geometry and surface 
area), pre-/post- dilution modes and all kinds of extracorporeal rheological conditions 
are additional factors that influence lifetime of hemofilters [30, 31, 54, 133]. For 
optimal cytokine removal frequent hemofilter changes and high-volume UFR has been 
recommended [23, 26, 32]. According to the data sheets of most hemofilters, 
replacement of hemofilter has to be done within 72 hours to maintain optimal 
membrane permeability. UFR per unit of membrane area might also contribute the FRT, 
it is defined as the UFR/Area (ml/h•m2) 
Hemofilters with greater surface area will usually provide higher filtration rate but have 
a greater tendency to clot in the case of low blood flow and increasing 
hemoconcentration when used in the post-dilution mode [57]. Hemofilters with high 
absorptive capacity also have a greater tendency to clot [71, 133]. 
 
2.7.6 Concentration polarization 
 
In CHF blood is exposed to a relatively large surface area of the filter membrane, the 
housing and potting materials for long periods of time. Interactions between blood 
components and hemofilter membrane can influence solute exchange in several ways:  
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(1) Blood flow along the surface will generate a “secondary” membrane (membrane 
fouling, including surface fouling and internal fouling) due to concentration 
polarization.  
(2) Exposure of blood to any foreign membrane can induce blood coagulation, 
complement activation and adherence of blood cells on the surface.  
(3) Shear stress between blood flow and membrane depends on the flow rate and blood 
viscosity may provide an adverse environment to the formation of the secondary 
membrane 
The secondary membrane and blood coagulation may worsen original membrane 
protein permeability depending on the MW of proteins, but shear stress might provide 
an inverse environment to the formation of secondary membrane. Therefore, higher 
blood flow rate may increase capillary shear stresses and reduce protein fouling [34, 129, 
143]. 
 
 
Figure 9: Secondary membrane formation and concentration polarization 
during hemofiltration. Jf: ultrafiltration flux, Cp: protein concentration. 
The secondary membrane formation during a convective renal replacement therapy is a 
dynamic process. Protein is moved to the membrane surface (polarized) in conjunction 
with the water permeating the membrane. Some other protein particles are moved away 
from the membrane by diffusion and shear stress from blood stream. In Figure 9 
thickness of the protein layer at steady state represents the net balance of these two 
processes (JC’p = K (Cp-C’p)) [50]. The ultimate thickness of the boundary layer is 
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determined by blood flow rate, ultrafiltration rate, hematocrit, plasma protein 
concentration, and mode of fluid substitution [24]. 
3 AIM OF THE STUDY 
 
Continuous hemofiltration (CHF) has limited filter running time (FRT) and steady 
increase of transmembrane pressure (TMP) to maintain the same ultrafiltration rate 
(UFR). This influences hydraulic and solute permeability of the hemofilter. Depending 
on the aim of CHF therapy, permeability of special solutes will also limit its 
performance even if hydraulic permeability is not yet reduced. 
It is the aim of this study to evaluate permeability of water and substances between MW 
10 000 to MW 70 000 in vivo. 
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4 PATIENTS AND METHODS 
 
4.1 Patients, machines and hemofilters 
 
30 ICU patients have been enrolled into the study protocol from May 2008 to 
September 2009. The study protocol was approved by the Research Ethics Committee 
of RWTH Aachen University.  
CHF treatment was carried out using three different dialysis monitors and hemofilters: 
1. Prismaflex® (Gambro Lundia AB, Lund, Sweden) machine equipped with AN69 ST 
150® membrane filter (1.5 m2). 
2. Multifitrate® (Fresenius Medical Care AG, Bad Homburg, Germany) machines, 
equipped with a polysulfone membrane ultraflux® AV1000S (1.8 m2). 
3. Prisma® (Hospal, Gambro Renal Products, Zaventem 1930 Belgium) equipped with 
AN69 M100® membrane (0.9 m2).  
 
4.2 Filtration rate and substitution fluid 
 
Filtrate rates were set around 1750 ml/h depending on the cardiological situation of 
patients. Warmed bicarbonated substitution fluids were administered in postdilution 
mode, containing 140 mmol/l of Na2+, 2.0 mmol/l of K+, 1.25 mmol/l of Ca2+, 0.75 
mmol/l of Mg2+, 111 mmol/l of Cl –, 35 mmol/l of HCO3 –, and 1.0 g/l of glucose. 
 
4.3 Collection of filtrate 
 
Every hour in the first 5 hours of each CHF treatment and every 5 hours in the rest of 
FRT, filtrate samples were drawn from the outlet of the hemofilter. Filtrate samples 
were stored at –20 °C until chemical analysis. 
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4.4 Analysis of filtrate 
 
All filtrate samples were subjected to total protein concentration measurements based 
on the Biuret method after precipitation with trichlor acetic acid (TCA). Albumin and 
β2 microglobulin concentration levels were measured using albumin immuno assay 
(Siemens, Marburg, Germany) and β2 microglobulin by enzyme immuno assay (Abbott, 
USA). High sensitive Sodium-dodecyl-sulfate-polyacrylamide-gelelectrophoresis (SDS-
PAGE) was done using Phast-System (GE) in modification by Melzer [78], protein 
with MW between 10 000 Dalton and 200 000 Dalton can be detected by SDS-PAGE. 
 
 
                      150 000                  65 000                30 000                 10 000 
 
Figure 10: One example for SDS-PAGE protein patterns in urine of a 
patient with severe tubular damage. β2 M: β2 microglobulin (MW: 11 818), 
RBP: retinol binding protein (MW: 21 000), α1 M: α1 microglobulin (MW: 
33 000), Alb: Albumin (MW: 65 000), Post-Alb: post-albumin (MW: 70 
000), Tf: Transferrin (MW: 78 000); IgG: immunoglobin (MW: 150 000). 
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4.4.1 Total protein 
 
The first step is the precipitation of the proteins in the filtrate with 20% solution of 
TCA. The test tubes are stored for at least six hours at 4°C to guarantee precipitation of 
all proteins. Following storage, the test tubes are centrifuged at 4.0 °C for 30 min. at 
3000 revolutions/ min. Following decanting of the supernatant, 5.0 ml of Biuret reagent 
is pipetted onto the protein sediment of each tube, and these were shaken for at least a 
minute on the rotary mixer until the sediment is completely dissolved in the Biuret 
reagent. 
The solutions were measured photometrically after an incubation time of 1 hour. The 
sample absorbances were measured at 564 nm in the photometer following their transfer 
in plastic cuvettes. 
The filtrate samples were subjected to protein concentration measurements based on the 
Biuret method. 
 
Materials and equipment  
- centrifuge (Heraeus Labofuge 400R, Osterode, Germany) 
- spectrometer (Perkin Elmer Lambda Bio UV/VIS, Überlingen, Germany) 
- rotary mixer (Eppendorf 3300, Germany) 
- polypropylene test tubes (13 ml volume) (Sarstedt, Germany) 
- photometer cuvettes  (10 • 10 • 45 mm), (Sarstedt, Germany) 
- pipettes and pipette-tips of varying sizes (Eppendorf, Germany) 
 
Reagents  
- 19.4% trichloracetic acid (Boehringer-Mannheim, Germany) 
- Biuret reagent (Boehringer-Mannheim, Germany) 
- Milli-Q water (Millipore, Germany) 
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The first step was the precipitation of the proteins in the filtrate. To achieve this, 
polypropylene test tubes were filled with 2.0 ml of 19.4% of TCA, and the centrifuged 
sample was pipetted into this millilitre by milliliter. As soon as protein precipitation 
occurred, purified water (Milli-Q water) was pipetted into this to make up a total 
volume of 10 ml. This assured a final standard 3.2% trichloracetic acid concentration in 
all test tubes, as well as a different dilution of each sample. The dilution factor of each 
sample could be determined from the volume (in ml) of the filtrate, which is added to 
the test solution, taking specifications of the manufacturer of the Biuret reagent 
(Boehringer-Mannheim) into consideration. The dilution factor plays a role in the later 
calculation of the protein concentration (e.g. a dilution factor of 5.0 results from 
precipitation from 1.0 ml filtrate with addition of 9 ml Milli-Q water; a dilution factor 
of 1.0 results from precipitation from 5.0 ml filtrate with addition of 5.0 ml Milli-Q 
water). The test solutions were stored for at least six hours at 4°C to guarantee 
precipitation of all proteins. 
Following storage, the test tubes were centrifuged at 4.0°C for 30 min. at 3000 
revolutions/ min. Following decanting of the supernatant, 5.0 ml of Biuret reagent were 
pipetted onto the protein sediment of each tube, and these were shaken for at least a 
minute on the rotary mixer until the sediment completely dissolved in the Biuret 
reagent. 
The solutions were measured photometrically after an incubation time of 1 hour. Pure 
Biuret reagent was used for the calibration of the photometer.  The sample absorbances 
were measured at 564 nm in the photometer following their transfer in plastic cuvettes. 
The measured sample absorbance allowed calculation of the total protein concentration 
(g/l) according to the following formula: 
  C (g/ l) = 373 × F × A × of 0.01   (Eq. 10) 
C:  concentration of protein, F:  dilution factor, A:  absorbance   
     
The normal range of protein in filtrate of Biuret method is about 50 mg/l ~ 1000 mg/l, 
values lower than 30 mg/l are out of detection accuracy of this examination. Protein 
concentration in the urine over 30 mg/l can be diagnosed for the proteinuria, the severity 
of which depends on the level of protein concentration.  
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4.4.2 Albumin  
 
Device and reagents 
- Nephelometer system 100 (Dade-Behring, Germany) 
- N/T protein control–low (human, code No.OQIN) (Dade-Behring, Germany) 
- N/protein control–medium (human, code No.OQIO) (Dade-Behring, Germany) 
- N/T protein control– high (human, code No.OQIP) (Dade-Behring, Germany)   
-  N protein standard SL (human, code No-OQIM) (Dade-Behring, Germany) 
The filtrate samples were completely thawed before measurement and centrifuged at 10 
800 rotations/min for 10 minutes. 300 μl of the supernatant and controls were pipetted 
into the reaction tubes separately, avoiding air bubbles. Then both patients’ samples and 
control samples were placed into the Nephelometer system for measurement - this is 
based on the program of Alb concentration in urine (mg/l). If the concentration of any 
sample exceeded the maximum limitation of measurement, then it was automatically 
diluted according to the chosen dilution range. 
The normal plasma concentration of the albumin is about 37 g/l ~ 52mg/l. The detection 
level of this measurement can be as low as 2 mg/l with control probe is set at 160 mg/l. 
 
4.4.3 β2 microglobulin (β2 M) 
 
The filtrate samples were subjected to β2 M concentration measurement according to 
the Microparticle Enzyme Immunoassay method (MEIA). 
Device and reagents  
  - Axsym system (Abbott, U.S.A) 
  - ß2 microglobulin MEIA kit (Abbott, U.S.A) 
Conduction of β2 M measurement 
Measurements of β2 M concentration by MEIA were performed according to the 
instructions in the kit. 
The filtrate samples were completely thawed before measurement and centrifuged at 10 
800 rotations/min for 10 minutes. 200 μl of the supernatant were pipetted into the 
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reaction tubes, avoiding air bubbles. Then the reaction tubes were placed into the 
Axsym system for measurement - this is based on the program of β2 M concentration in 
serum or urine (mg/l). Three positive controls were contained for each run, which 
indicated low, medium and high values of measurement. If the concentration of the 
sample was below the minimum limitation of measurement, then the sample was 
subjected to another program, which could detect the lower level of β2 M. 
Normal plasma concentratrion of β2 M ranges from 2.0 to 3.2 mg/l [3]. The detection 
limit of this assay is 0.2 mg/l.  
 
4.4.4 SDS-PAGE 
 
Principle 
The sodium-dodecyl-sulfate-polyacrylamide-gelelectrophoresis of Shapiro et al. 
employs mainly protein molecular weight as opposed to protein molecular charge as the 
separation criterion. This approach was found to be reliable over the past few years 
regarding the differentiation of urine proteins [14]. In the SDS-PAGE used here, the 
proteins are denaturized by mixing of the samples with sodium-dodecyl-sulphate (SDS) 
and are transformed into molecule detergent micelles. Tertiary and secondary structures 
are dissolved through splitting of the hydrogen-disulphide bond in the polypeptide 
chain; this compensates for the differences in protein molecular form. Protein charge is 
effectively masked by the action of the anionic agent, and anionic micelles with 
constant net charge per mass unit (approx. 1.4 g SDS per 1 g protein) develop. All 
fractions migrate towards the anode due to this standard negative charge [14]. 
Furthermore, protein aggregation is prevented [108]. 
In this study, the electrophoresis separation is conducted in prefabricated "Phast" gels. 
These are ultrathin gels with a continuous polyacrylamide gradient of 8 ~ 25% T and a 
cross-linking of 2% C. The protein molecules become separated according to their 
molecular weight during migration towards the anode in direct current due to a 
continually decreasing pore size within the gel. The rate of migration is inversely 
proportional to the molecular weight of the proteins [89]. Pore-gradient-gels have better 
separation capabilities than gels with fixed pore diameters. In addition, pore-gradient-
gels counteract molecule diffusion so that a sharper distinction between the zones is 
achieved [89, 110]. Ultrathin horizontal gels have the further advantage that they can be 
 38
more effectively cooled and, consequently, can be subjected to a higher electric field 
strength; this increases the resolution. The sensitivity of the analysis in combination 
with the silver dye is so high that further concentration of the filtrates is not necessary. 
This not only saves time but also improves reproducibility, as further concentration 
steps can result in the loss of some molecules, especially low molecular weight proteins 
[14, 115, 136]. 
SDS-PAGE is a very sensitive method to detect protein of MW between 10 000 and 
150 000 even in quite low concentration, in the urine or filtrate [79]. 
Materials and apparatus 
 - Phast system (Pharmacia, Uppsala, Sweden) 
 - native and SDS agarose buffer strips 
 - 8-25% pore-gradient-gel for the Phast system 
 - sample tray 
 - 8/1 sample applicator for the Phast system 
 - centrifuge for Eppendorf caps  (Abbott, Germany) 
 - Eppendorf caps 
 - powder-free latex gloves 
 - tweezers 
- 602 H - filter paper (Schleicher and Schuell) 
Reagents 
Analytically specified chemicals and reagents from Merck (Darmstadt, Germany) were 
used for the production of the dyeing and buffer solutions. Other reagents used are:  
 - Triton X-100 (Sigma Chemical Company, St. Louis, USA) 
 - Milli-Q water (Millipore, Germany) 
 - kerosene for coating of the cooling plate 
Fixation and buffer solutions 
 Buffer for sample dilution, [pH] 7.2: 
 - 0.64 mol/l triacetate solution adjusted to pH 7.2 with 100% acetic acid  
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 - 0.032 mol/l EDTA-disodium salt  
Dilute 1:16 with Milli-Q water before use. 
 
5% SDS buffer solution: 
 - 36 g urea 
 - 5.0 g SDS 
 - 12.5 mg bromphenol blue  
Solutions for silver-dyeing according to Heukeshoven [60], modified according to 
Melzer [61]: 
1) Fixation solution I: 
 - 60 ml 30% isopropanol (analytical grade)  
 - 20 ml 100% acetic acid glacial 
 - 12 ml 37% formaldehyde 
 - Milli-Q water add to 200 ml 
2) Fixation solution II: 
 - 100 ml 60% isopropanol solution 
 - 100 ml 20% acetic acid solution 
3) Conditioner according to Heukeshoven: 
 - 30 ml 100% ethanol solution 
 - 10 ml 4 mol/l sodiumacetate solution 
 - 5 ml 37% formaldehyde solution 
 - 200 mg sodiumthiosulphate-pentahydrate  
 - Milli-Q water add to 100 ml 
4) Washing solution: 
 - 30 ml 30% isopropanol solution 
 - Milli-Q water add to 200 ml 
5) Rinsing solution: 
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 - Milli-Q water 
 
6) Silver stain solution:  
 - 1.0 ml 25% silver-nitrate solution 
 - 200 µl of 37% formaldehyde solution 
 - Milli-Q water 249 ml 
7) Developing solution: 
 - 25 ml 1.2 mol/l sodium-carbonate solution 
 - 200 µl 37% formaldehyde solution 
 - Milli-Q water add to 100 ml 
8) Stop solution:  
 - 18.6 g EDTA disodium salt 
 - 24.2 g Tris-hydroxy-methylaminomethane (Tris-base) 
 Milli-Q water add to 1000 ml 
9) Conservation solution:  
 - 141.0 g 87% glycerol solution 
 - 10 ml sodium azide 
 - Milli-Q water add to 1000 ml 
 
Principle of silver-staining 
Numerous modifications of the original silver-staining process have been developed; 
these aim to improve detection limits for proteins, increase reproducibility and reduce 
non-specific staining of the gel matrix [62]. Major improvements are the primary 
incubation of proteins with a silver-nitrate solution at neutral pH, followed by a 
reduction of the silver ions in a strong basic pH. Increased silver ion binding to proteins 
can be attained through the use of bifunctional glutaraldehyde with activation of the 
covalent bonds.  
The modified silver-staining used here [64] is in essential that adapted by Heukeshoven 
and Dernick for the staining unit of the Phast system [52]. Detection of especially low 
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molecular weight proteins can be significantly improved using this modification 
together with the Phast system [14, 110, 141]. 
The non-specific binding of silver ions on organic and inorganic deposits in the gel 
matrix poses a problem in the silver stain process, as this complicates measurement is 
no longer possible [64, 110]. As described by Heukeshoven and Dernick in 1988 [52], 
non-specific background staining can be lessened using sodium sulphate to reduce the 
oxidative characteristics of the gel matrix. A further reduction of the background 
staining is attained here using an advancement of the method of Melzer [64]. Details of 
the silver staining are as follows: 
- Use of isopropanol instead of ethanol for the fixation of the proteins as well as in the 
first two rinsing steps; in addition to protein denaturization, this overcomes deposition 
of non-specific substances from the gel matrix. 
- Following the silver staining step, and in contrast to the method employed by 
Heukeshoven and Dernick [52], the surplus silver nitrate solution is then rinsed off. 
- The reduction of silver ions on proteins and the non-specific binding of silver ions can 
be slowed down in the developing phase by lowering the incubation temperature to 
15°C and reducing the incubation time in the first step to 0.4 minutes and in the second 
step to 3.6 minutes. After this, the silver ions remaining in the gel matrix can be washed 
out as binding of these to the gel matrix is weaker and takes longer than their binding to 
proteins. 
- The development process here is stopped by the combined application of an EDTA 
buffer solution.  The formation of chelates stops development on the one hand, but also 
removes free metal ions and insoluble salt deposits from the gel matrix. 
Excessive silver ion removal by rinsing was not observed in the modification applied 
here [64]. In this modification, it is no longer necessary to interrupt the staining process 
by the introduction of blue toning solution so as to manually counteract any background 
coloring, as was described by Heukeshoven and Dernick [52]: the whole staining is 
conducted automatically using the Phast system and takes approximately 70 minutes. 
This highly sensitive method allows subsequent use of laser densitometry as non-
specific staining is reduced, sensitivity increased and reproducibility is improved. Even 
protein concentrations under 50 mg/l, as occurs in cases of tubular proteinuria, for 
example, can be detected [76, 80]. 
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Description of the Phast electrophoresis and staining system 
The Phast system used here is a semiautomatic electrophoresis and staining system 
consisting of a horizontal electrophoresis chamber with a cooling plate and a stain 
chamber. Different currents, temperatures for separation and staining and various 
staining methods can be programmed and initiated. The stain chamber comprises nine 
entry ports and one exit port for the staining solution (corresponding to the numbering 
under 3.4.2.4). 
 
Conduction of the SDS-PAGE 
Filtrate samples with protein concentrations in excess of 0.5 g/l were diluted with 
sample buffer solution to a concentration of 0.5 g/l. All other samples were not diluted. 
400 µl of the filtrate sample (diluted or undiluted) were placed in Eppendorf vessels, 
100 µl SDS buffer solution was added and all was mixed on the rotary mixer. The 
mixtures were then incubated at room temperature for 12 hours. 
The cooling plate of the separation chamber was coated with 100 µl kerosene for the 
application of the gels (2 gel plates per electrophoresis) and to improve gel cooling 
during separation. This was followed by application of the gels, taking care to avoid air 
bubbles, and their positioning within the markings. Surplus kerosene was absorbed with 
blotting paper and the protective foil was removed from the gel plates. Then the buffer 
strip holder was attached and the native and SDS buffer strips were inserted by applying 
a slight pressure. Gloves were worn to avoid contamination. The electrodes were then 
lowered onto the buffer strips.  
The filtrate samples mixed with 5% SDS were centrifuged at 10 800 rotations/min for 
15 minutes to remove precipitated crystal deposits. 3.4 µl of the supernatant were 
pipetted into the sample tray wells. One gel of each run contained a standard of 
monomeric hemoglobin (Merck). About 1.0 µl of each of the prepared mixtures, in 
accordance to the manufacturer's instructions, was transferred to the appropriate 
position in the separation chamber by the dipping of a special applicator device into the 
tray wells. Each gel plate could be loaded with a total of eight filtrate mixtures. 
Automatic simultaneous application of the filtrate mixtures onto the gel occurred at the 
programmed time after start of electrophoresis. The 10 mA induced protein separation 
was stopped when the buffer front reached the anode. This electrophoresis lasted 30 
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minutes. The movement of the sample material in the electric field could be easily 
observed due to the stain (bromphenol blue) in the SDS solution.  
Following separation, all used machine parts were thoroughly cleaned with extran 
(1:100) to remove any residual proteins. 
 
The staining process   
The fixing, conditioning, wash, silver stain and developing solutions were freshly 
prepared prior to each staining process, partly using prepared stocks. Such stock 
solutions, as well as the stop and conservation solutions, were filtrated through paper 
filters before use. The developing solution was stored in a refrigerator at 4°C until 
shortly before use. Formaldehyde was added to the silver stain and developing solutions 
only immediately before their inclusion in the staining process. 
Following electrophoretic separation of the proteins, the two gel plates were carefully 
transferred to the staining chamber using tweezers. The staining process was started 
after the bottles with the different solutions (1~9) were attached to the respective ports 
in the staining chamber.  
After conclusion of the staining process, the gels were moistened with a drop of purified 
water and the protective foil, which was removed earlier was replaced. Storage followed 
in covered petri dishes in a cool, dark environment.  
 
Densitometric evaluation 
The laser densitometric evaluation which is conducted immediately after SDS-PAGE 
translates the protein zone pattern into an informative curve diagram [15, 139]. The 
electronic file of the registered protein patterns enables their continual reproduction; the 
protein pattern thus remains unaffected by any later darkening of the gel and this has 
proved to be particularly helpful for observations of the actual process. If required, a 
number of densitogrammes could be overlaid to facilitate a more direct comparison of 
protein patterns taken at different times [115]. The zone pattern can hereby be more 
exactly compared than by eye. The significantly reduced background dyeing resulting 
from the modified silver dyeing employed here allowed an improved semiquantitative 
evaluation, as the so-called "dye baseline" was clearly reduced in the densitogrammes. 
A complete quantification is difficult to attain as protein concentration is not directly 
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proportional to color intensity at high protein concentrations [64]. Furthermore, 
different protein molecules have different affinities for silver ions [136]. However, 
some quantitative evaluation is possible with the use of standardized protein solutions 
of varying concentrations which are simultaneously separated, together with the 
application of specialized software [108]. Unfortunately this is not feasible in routine 
practice.  
 
The following equipment is required for the densitometric evaluation: 
- laser densitometer  (Ultrascan XL, Pharmacia Biotech, Uppsala,                   
     Sweden) 
 - PC with Gel-Scans-software "Image-Master" version 1.2 (Pharmacia  
 Biotech) 
 - laser printer (Hewlett Packard). 
 
Densitometers are movable photometers, which scan the separation zones in gels. The 
optical densities of the individual lanes and the relative migration distances are 
measured. The employment of laser light has the advantage of a high resolution as the 
intensity of even very narrow light rays is high and, consequently, linear measurements 
are delivered. 
Densitogrammes were produced according to the instructions in the manufacturer's 
handbook. The protective foil was removed from the gel plates, these were moistened 
on the bottom with distilled water, and were then placed air-tight on the measuring table 
of the densitometer. The gel plates were so positioned that the guide line of the grid lay 
in the middle of the separation track. Measurement of the optical density of the so 
programmed tracks was then started. Data transfer to the computer followed 
automatically. The data were translated into curve diagrams, which were then saved for 
further use after scanning of the bands using special data processing software. The 
relative areas of the different peaks and the total area of the integration curve could be 
calculated. In samples of very low protein concentration, which had an increasing dye 
baseline, a special subroutine could suppress the resultant area in the densitometer so 
that the relative peak areas were not distorted.  
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Figures 11 and 12 show the different patterns of urine under varying conditions. 
 
 
Figure 11: Different protein patterns in SDS-PAGE gels. 
Indicators of Figure 11: 
1. Unselective glomerular and partial tubular damage 
2. Unselective glomerular damage with dimeric albumin 
3. Selective glomerular damage 
4. Unselective glomerular and total tubular damage (with ß2 microglobulin) 
5. Unselective glomerular and partial tubular damage 
6. Albumin (total protein concentration > 50 g/day) 
7. and 8.  Normal pattern (total protein concentration ≤ 50 g/day) 
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Figure 12: Different protein peaks in laser densitomer diagrams. 
 
Indicators of Figure 12: 
1. Albumin 
2. Low molecular weight protein, MW 30 000 ~ 50 000 (partial tubular) 
3. Low molecular weight protein, MW 10 000 ~ 68 000 (total tubular) 
4. Monomeric hemoglobin 
5. Monomeric Ig G 
6. Light chain 
7. Transferrin and albumin 
8. Immunoglobulin  
9. Transferrin 
SDS-PAGE allows detecting peptides and proteins with very high sensitivity even at 
total protein concentration below 30 mg/l. 
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4.5 Statistics 
 
The statistical analyses are based on mean + standard deviation. Comparisons between 
different hemofilters in TMP were carried by Student t-test, survival percentages of 
different hemofilters depending on time were shown by Kaplan-Meier curves drawn 
with software Graph Pad Prism 5®. The difference is significant for p <0.05. In results 
of total protein concentration and β2 M concentration were shown by the means of one-
way analysis of variance (ANOVA). 
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5 RESULTS 
 
The clinical characteristics and outcome of patients are summarized in Table 3. All 
patients suffered from acute renal failure combined with sepsis or SIRS. They all have 
low hematocrit and hypoproteinemia with reduced plasma albumin. 19 out of 30 
patients (63.3 %) died before the end of three weeks after their enrollments. Total 
treatment time ranges from 9 hours to 3 weeks. The mean value of CHF treatment time 
is 10 days.  
         
 
Multifitrate®; 
AV1000S® 
Prismaflex®;        
ST 150® 
Prisma®;         
M 100® 
Number of patients  17 8 5 
Age (years) 65.9 + 14.5 61.9 + 16 61.8 + 9.9 
Main Diagnosis ARF, sepsis ARF, sepsis  ARF, sepsis  
Quick-Test (sec) 55 + 24.9 74.1 + 27.2 59.1 + 31.2 
PTT-Test (sec) 53.7 + 20 43.4  + 13.4 44.9 + 6 
Hematocrit (%) 27 + 2 26.7  + 2.3 29.3 + 3.7 
pH 7.31 + 0.10 7.40  + 0.04     7.3  + 0.07 
Total protein (g/l) 48.6 + 11.8 47.6 + 7.3 50.2 + 4.2 
Albumin (g/l) 21.6 + 3.1 26.0 + 4.5 23.5 + 3.5 
Cholesterol (mg/dl) 87.7 + 30.7 88.3 + 38.0 114.7 + 47.1 
Triglycerides (mg/dl) 128.1 + 75.3 109 + 28.1 122.3 + 11.6 
Thrombocytes (Giga/l) 217.1 + 143 220 + 151 226.2 + 14.2 
CRP (mg/l) 170 + 52.3 99.6 + 39.4 134.8 + 49.8 
Urea (mg/dl) 145 + 98 107 + 42 110 + 15 
Creatinine (mg/dl) 3.8 + 5 2.4 + 1.4 2.1 + 1.4 
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Table 3: Laboratory data of patients. Quick –Test: prothrombin time, PTT-
Test: partial thromboplastin time, CRP: C-reactive protein. 
 
The technical data of CHF are shown in Table 4. All patients have been treated in the 
post-dilution mode with equivalent dosage of heparin. The daily rate of ultrafiltrate is 
40 ~ 45 l. 
 
 
Multifitrate®; 
AV1000S® 
Prismaflex®; 
ST 150® 
Prisma®; 
M 100® 
Qbi (ml/min) 163 + 29 159 + 20 143 + 18 
Qf  (ml/h) 1896 + 309 1692 + 197 1675 + 283 
Qf/day (l) 45.5 + 7,4 40.6 + 4.7 40.2 + 6.8 
Filtration fraction (%) 19.4 17.7 19.5 
Heparin (IU/hour) 919.5 + 402 1125 + 586 1125 + 177 
Dilution mode post post post 
 
Table 4: Mean values of technical data. Qbi: extracorporeal blood flow 
entering the hemofilter, Qf :  filtrate rate, Filtration fraction: Qf / Qbi, 
Qf/day: volume of ultrafiltrate per day. 
 
5.1 Hydraulic permeability  
 
The hydraulic permeability of the filters can be calculated from the UFR and the TMP, 
which is necessary to obtain a certain fitration rate. 
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Figure 13: Changes in TMP of different hemofilters. 
Figure 13 shows the linear increase of TMP, which is necessary to maintain a constant 
filtration rate. The TMP in ST 150® and M 100® are higher than that in AV 1000S®. 
After 25 hours, TMP in AV1000S® and ST 150® keeps rising. TMP value in ST 150® 
is still around 20 mmHg higher than AV1000S®. Overall, TMP in AV1000S® increases 
very steadily depending on treatment time.  
 
Multifitrate®; 
AV1000S® 
Prismaflex®; 
ST 150® 
Prisma®; 
M 100® 
UFR/Area (ml/ h·m2) 1053 + 172 1128 + 131 1861 + 314 
FRT (h) 51.2 + 18.3 47.1 + 23.2 16.8 + 7.1 
 
Table 5: UFR/Area and FRT. Mean values of each hemofilter. 
 51
Table 5 shows mean FRT and UFR/Area of each hemofilter. Here it can be seen that 
M 100® has the highest amount of ultrafiltrate per area, which is the one with the 
shortest FRT.  
 
 
Figure 14: Kaplan-Meier survival curves of FRT for each hemofilter. 
 
As shown in Figure 14 there is no significant difference in FRT between AV1000S® 
and ST 150® (p>0.05) whereas the difference of between M100® and AV1000S®/ ST 
150® is significant (p<0.0001). 
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Figure 15: Relation between FRT and UFR/area of each individual 
hemofilter. 
 
In Figure 15 each FRT point is noted with its respective UFR/Area. Inverse 
relationship between FRT and UFR/Area is found in all hemofilter groups. AV1000S®, 
with longest mean FRT, shows less dependency of FRT on UFR/Area than ST 150®. 
M100®, with shortest mean FRT shows smallest dependency of FRT on UFR/Area.  
From these data it can be concluded that UFR/Area of about > 1500 ml/ (h·m2) is 
associated with FRT < 24 hrs in all hemofilter types. 
Summary: For each membrane increasing TMP is necessary to compensate decreasing 
hydraulic permeability and FRT is negatively associated with higher ultrafiltration rate 
per membrane area.  
 
5.2 Solute permeability 
 
Solute permeability has been tested for total protein, albumin and β2 M as absolute 
measurements and using SDS-PAGE as relative measurement with high sensitivity. 
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Proteins amounts in the filtrate are dependent on unwanted protein loss and wanted 
removal of toxic low molecular weight proteins and peptides. 
 
5.2.1 Total protein 
 
As is shown in Figure 13 total protein in the filtrate is high only at the beginning of 
filter running in AV1000S® and ST 150®. After 5 hours protein loss is less than 30 mg/l 
or about 1.2 g/day in all hemofilters.  
 
Figure 16: Total protein in filtrate. 
 
From Fig 16 mean total protein concentration in filtrate of AV1000S® declines from 
160 mg/l at the beginning to 53.3 + 17.7 mg/l within 5 hours, it further declines to 29.6 
+ 9.9 mg/l after 6 hours and lasts relatively stable (28.5 + 13 mg/l) till the end of 
application time. The decrease of concentration is only significant in the first 5 hours. 
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For ST 150®, the mean total protein concentration decreases from 74.7 + 68.1 mg/l at 
the beginning to 42.8 + 18.8 mg/l within 5 hours, it further goes down to 32.3 + 7.6 mg/l 
after 6 hours and stays at this level for the rest of application time. The decrease is also 
significant in the first 5 hours. 
In M 100®, mean total protein concentration is 9 + 2.8 mg/l at the beginning, which is 
much lower than that in the other hemofilters. It shows little differences according the 
whole FRT. There is no significant change throughout the whole application time. 
 
5.2.2 Albumin 
 
Table 6 shows changes of albumin concentration in filtrate. Albumin concentration in 
filtrate can reach 0.08 g/l from AV1000S® at the beginning of application. It goes down 
very quickly to below 0.002 within 5 hours. For ST 150®, albumin concentration is low 
at the beginning, compared to that of AV1000S®. It decreases below the detection limit 
after 24 hours. Albumin of M 100® is always below the detection limit. 
 
 1/2 h 5 h 24 h 48 h After 48 h 
AV1000S® 0.08 <0.002 <0.002 <0.002 <0.002 
ST 150® 0.005 0.002 0.002 <0.002 <0.002 
M 100® <0.002 <0.002 n.a. n.a. n.a. 
 
Table 6:  Albumin in filtrate (g/l). Due to the sensitivity of the measurement, 
values bellow 0.002 g/l can not be detected, n.a.: data is not available.  
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5.2.3 β2 microglobulin 
 
 
 
 
Figure 17: β2 M in filtrate. 
 
From Figure 17 the mean value of β2 M in filtrate from AV 1000S® is 5.6 + 3.0 mg/l at 
the beginning of application, it decreases to 3.1 + 0.8 mg/l after 48 hours. 
For ST 150®, the mean value decreases continuously from 6.4 + 1.1 mg/l at the 
beginning to 3.0 + 0.9 mg/l in the end. 
Different from the behaviour of the other hemofilters β2 M concentration in filtrate of M 
100® increases significantly during treatment. The mean value in filtrate is 0.9 + 0.1 
mg/l at the starting point and keeps going up to 2.5 + 0.2 mg/l in the end of its life-time. 
The general mean values of β2 M concentration in filtrate of M 100
®are significantly 
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lower than those in the other hemofilters (p<0.05). After 24 hrs they are about three 
times as high as in the beginning. In any case, after 24 hrs concentration of β2 M in 
filtrate returns to the normal plasma concentratrion (2.0 ~ 3.2 mg/l).  
 
5.2.4 Protein patterns in SDS-PAGE 
 
 
Figure 18: SDS-PAGE protein patterns in filtrate of different hemofilters 
with progression of time 
Figure 18 shows typical protein patterns of each membrane during FRT.  
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As can be seen in the AV 1000S® filter only at start albumin can be detected in filtrate. 
But proteins and peptides of MW 10 000 to about MW 20 000 can be detected even 
after 48 hrs of filter running.  
Similar protein distribution can be found in ST 150® filters. In this membrane, RBP 
(MW 21 000) is also found after 48 hrs. Decreasing peaks of albumin can be found 
within 5 hrs. α1 M, and β2 M peaks are stable in different stages of therapy.  
In the M100® filter albumin is seen after 5 hrs. Here also proteins and peptides of MW 
up to 30 000 can be detected after 5 hrs.  
Summary: Each membrane is permeable for proteins and peptides up to about MW 30 
000 throughout their running time. In the uncharged AN69 (ST 150®) membrane there 
is increasing height of β2 M peak in the filtrate within the first 5 hours. 
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6 DISCUSSION 
 
Whereas the human kidney is able to deliver about 180 l of filtrate everyday for 
decades, in CHF lifetime of hemofilters is limited from some hours to a few days. This 
is due to problems in anticoagulation, bioincompability of the membrane and membrane 
fouling. In order to maintain a filtration rate similar to the natural kidney, the properties 
of the extracorporeal blood detoxication device have to be optimized with regard to 
hydraulic and solute permeability. Especially in acute renal failure in septic patients not 
only low molecular weight uremic toxins but also higher molecular weight toxic 
substances have to be removed. 
 
6.1 Hydraulic Permeability 
 
Convection of water and solutes during hemofiltration is driven and maintained by 
TMP. In this study the hydraulic permeability of each filter continuously declines and a 
linear increase of TMP is necessary to keep filtration rate constant. This effect of 
decreasing hydraulic permeability is more pronounced in the hemofilter with highest 
filtration rate per area of membrane of (Lh) and negative charge of the membrane 
polymer. Decreasing UFcoeff during CRRT also has been confirmed by others [74]. 
Decrease of hydraulic permeability is due mainly to the protein absorption on the 
membrane. Absorptive surface of a membrane resides primarily in its pore structure 
rather than in its external surface area, and absorption of any middle or low molecular 
weight protein will depend on it having access to the membrane internal pore structure 
[22]. Especially in the M100® hemofilter there is increasing concentration of β2 M in 
the filtrate indicating absorption of this molecule inside the membrane during the initial 
hours of treatment. When after about 10 hours the membrane is saturated with β2 M [95] 
this substance appears in the filtrate nearly at the same concentration like in 
hemofiltration using the other membranes. This phenomenon also has been described by 
Xu [142]. In the other non β2 M absorbing membranes, there is decreasing 
concentration of β2 M in the filtrate. In this sense β2 M can be used as a marker of 
absorption capacity of this negatively charged membrane. Hydraulic permeability is 
approximately proportional to the fourth power of mean membrane pore radius. Thus 
small changes in pore size have large effects on the membrane UFcoeff [71]. Transport of 
substances to the inner pores also depends on the filtration rate, which generates the 
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convective transport of solutes to the pores of the membrane. Therefore it seems 
understandable that in the hemofilter with highest UFR/Area (M100®) there is strongest 
decrease in hydraulic permeability and shortest filter running time. Therefore absorption 
of substances inside the membrane might not be advantageous for maintaining hydraulic 
permeability and life-time of a hemofilter. 
A lot of studies have been performed on the impact of UFR/Area on FRT as can be 
seen in Table 9. Overall data on FRT in literature are contradictory because of different 
modes of anticoagulation [90, 107], blood flow  [7, 54, 93], membrane area [34], blood 
access [30], filtration fraction [31, 125, 130], mode of dilution [56] and membranes 
[112]. From more than 20 publications in the last 17 years using heparin as 
anticoagulant data about the relation between FRT and UFR/Area are shown in Figure 
19.  
From these data and from our data the relationship between UFR/Area and FRT is 
analyzed as shown in Figure 19. There is a hyperbolic relation between UFR/Area and 
FRT. Each blue point represents the mean value from the results (mean FRT & mean 
UFR) of one publication [7, 11, 31, 34, 36, 65, 66, 70, 82, 84, 85, 117, 125, 130, 131, 
135], each red point stands for the mean values of three hemofilters in this study. It can 
be concluded that higher UFR/Area induces more protein absorption and formation of a 
secondary membrane [61] and therefore shorter FRT. 
FRT has already been taken as an quality indicator for CRRT in order to reduce circuit 
“down-time” per day [66, 124]. The prescribed dose of treatment should be delivered to 
the patients, which asks for ultrafiltration of at least 35 ml/(kg·h) [99]. 
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Figure 19: Non-linear regression between UFR/Area and FRT  
 
In Figure 19 three examples are demonstrated by the hemofilters applied in this study. 
Depending on mean body dry weight (kg), ultrafiltration dose recommended (e.g. 
35ml/(kg·h)) and respective surface area of hemofilters, UFR/Area of each hemofilter 
can be calculated [99]: 
body ultrafiltration
surface
W D
AUFR/Area=
•
      Eq. 11 
Wbody: body weight patient (kg), Dultrafiltration: ultrafiltration dose 
recommended (ml/h/kg), Asurface: surface area of hemofilter (m2). 
Therefore, three vertical lines are generated by their UFR/Area in different colors and 
intersect the black curve at points “A”, “S” and “M” (A stands for AV1000S®, S for ST 
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150®; M for M100®). Because of its small surface area, M100® (AN69HF) might 
produce clotting within 12 hours due to the highest UFR/Area under prescribed 
ultrafiltration dose necessary for the 68 kg adult and continuity of treatment is 
problematic. It has the smallest priming volume of three hemofilters in our study and 
might be more suitable to the patients, whose body weight is below 40 kg. Therefore, in 
order to improve the outcome of critical patients in ICU, prescription of both sufficient 
dose of ultrafiltration and UFR/Area of hemofilters should be considered. The selection 
of the hemofilter size has to be relevant to the body weight of patients. For prescribed 
ultrafiltration dose, higher body weight of patient, larger surface area of hemofilter is 
preferred. As long as absorptive properties of the membranes cannot be optimized, 
UFR/Area should not exceed 1500 ml/ (h·m2). 
In summary, the data sheet of each hemofilter should be specified about its upper limit 
of ultrafiltration rate. In order to improve the outcome of critical patients in ICU, 
prescribed dose of ultrafiltration and UFR/Area of hemofilters should be taken into 
consideration. 
 
6.2 Solute permeability 
  
In continuous filtration therapy loss of physiological (vital) proteins should be 
minimized and removal of low and middle molecular weight uremic toxins and peptides 
should be optimized [134]. 
As can be shown in this study in all filters total protein is found in the filtrate only in the 
first hours of treatment. After 5 hours, it is less than 50 mg/l corresponding to 1.5 ~ 2.0 
g/day. Loss of albumin is less than 100 mg/day. Therefore hypoproteinemia and 
hypoalbuminemia of these patients can be explained rather by malnutrition than by 
albumin loss through the hemofilter membrane. Decrease in protein permeability during 
the initial hours of treatment can, like decrease in hydraulic permeability, be explained 
by secondary membrane formation inside and outside the hollow fibres as the result of 
protein deposition [98]. 
Clearance of low molecular weight uremic toxins (SC = 1.0) like urea and creatinine 
corresponds to the filtration rate of about 40 l/day or 280 l/week. This is superior to 
weekly urea clearance in standard intermittent three times /week, 4 hours maintenance 
hemodialysis therapy of about 150 l/week (Kt/V about 1.3). In this way renal 
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replacement therapy with all investigated membranes is optimal and consequently urea 
and creatinine concentration of the patients is low (see Table 3). 
Of special interest in ARF in septic patients is removal of MM and inflammatory 
cytokines. Convective clearance of middle molecular weight uremic toxins depends on 
UFR and SC. Troyanov et al have found a stable SC of β2 M around 0.62 also in M 
100® with different UFR (1~4.5 l/h) [121]. Padrini has shown that a stable SC (pre-
dilution: 0.55 vs. post-dilution: 0.65) independent of time (4 hour treatment) can be 
detected in Polyflux 21S® [91].  
Because of their very low molar concentration, middle MW uremic toxins only can be 
removed by convection or absorption. As a marker of these substances β2 M has been 
investigated. β2 M  concentration levels in filtrate of AV 1000S® and ST150® show 
continuous decline with time to physiologic concentration, whereas in M100® it 
increases from a low value up to physiologic concentration (see Figure 17). It can be 
concluded that removal of β2 M in AV 1000S® and ST 150® is done mainly by 
convection whereas in M 100® β2 M is mainly absorbed by the membrane. Nevertheless 
Randoux et al. have found in an in-vitro bulk absorption of M 100® equal to ST 150® 
[95]. Lavaud et al. have shown similar results from AN69ST® and think it is due to the 
special binding ability of heparin of to the AN69 ST® membrane [71]. 
However, the permeability of hemofiltration membranes cannot be always characterized 
by molecular weights of substances in the filtrate, several other factors also affect 
permeation through these membranes: shape of the molecules and pH of solution. When 
membrane retention measurements are performed with linear, water-soluble molecules 
such as polydextran, polyethylene glycol, or polyvinylpyrrolidone, the measured 
rejection is much lower than the rejection measured for proteins of the same molecular 
weight as protein molecules have tightly wound globular coils held together by hydrogen 
bonds. These globular molecules cannot deform to pass through the membrane pores and 
are rejected. Therefore, the 3-dimensional shapes of all kind of cytokines have to be 
taken into consideration. For example, TNF-α exists in blood circulation as a biological 
trimer of MW 54 000, one trimer can resolve into 3 nonactive monomer of MW 17 000 
and the main structure chain of one IL-8 monomer contains a heparin-binding domain 
[6], its molecular weight will increase in the case of binding to the heparin. Therefore, 
the cytokine clearances from different studies show different results [32, 46, 123]. The 
pH of the solution is another factor that affects permeation through the hemofilter 
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membrane [6], it has been assumed that there were little influences from pH to 
permeation of cytokines in our study. 
 
In Table 7, SC of different cytokines is dependent on the molecular weight cut-off of 
hemofilter instead of their respective MW. 
As can be seen in SDS-PAGE (see Figure 18), middle molecules of up to MW 30 000 
can be detected at any time in the filtrate. Therefore it has to be concluded that although 
there is steady decrease in hydraulic permeability due to secondary membrane 
formation, removal of so-called MM is maintained until the end of FRT. This also may 
include proinflammatory cytokines like IL-1 IL-8, IL-6, IL-10 and TNF-α. 
It has been claimed that in ARF patients with sepsis also proinflammatory cytokines 
should be removed. Sieving coefficients from different in-vivo experiments ranging 
between 0 and 0.81 are summarized in Table 7. 
A number of trials have been done with contradictory results. Uchino et al. have found 
that SC > 0.6 can be achieved for IL-1ß, IL-6 and IL-10 and SC > 0.3 is reached for 
IL-8 and TNF-α with 1 l/h of ultrafiltrate. SC of almost all cytokines are reduced when 
the ultrafiltration rate has been increased from 1 l/h to 6 l/h [123]. Cytokine clearances 
from different studies show different results [32, 46, 123]. Many studies examining 
cytokines in the ultrafiltrate [48, 97, 104, 132] have shown that cytokine plasma levels 
do not decline in septic patients, despite elimination of cytokines by CHF. In HVHF 
cytokine concentration in plasma water and mortality has been reduced in severe septic 
shock patients, compared to CHF [23, 26, 40, 55]. 
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Membrane MWCO UFR (l/h)  Sieving coefficient of Cytokines 
   IL-8   
(MW=8 000)
TNF-α*  
(MW=17 000) 
IL-1      
(MW=17 000)
IL-10  
(MW=35~40 000) 
IL-6    
(MW=26 000) 
1 (pre-) 0.31 0.27 0.81 0.56 0.73 
PA [123] 100 000 
6 (pre-) 0.19 0.09 0.75 0.56 0.32 
PA [53] 30 000 variable 0.25 0 0.18 n.a. 0 
PSu [48] 30 000 1 (post-) 0.12 0.22 0.42 0 0.04 
AN69 [32] 35 000 1.5 (post-) 0.08 0.16 0.22 0 0.18 
 
Table 7: Sieving coefficients of cytokines in different membranes. MWCO: Molecular weight cut-off; UFR: ultrafiltration rate; 
pre-: pre-dilution; post-: post-dilution; TNF-α*: TNF-α monomer; PA: polyamide; PSu: polysulfone; n.a.: not available
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It is an open question if removal of proinflammatory cytokines is possible in an 
adequate way. In contrast to metabolic end products like urea and creatinine, specific 
kinetics of these substances has to be taken into consideration. Cytokines are generated 
in sepsis very quickly. Once produced in the tissue, they are rapidly consumed through 
interaction with numerous surface-receptors of cells or circulating natural inhibitors and 
proteinases resulting in a plasma half-life from 6~20 min [13, 47]. They are 
characterized by very low molar plasma concentration and high endogenous non-renal 
clearance. Therefore plasma concentration of cytokines may be more dependent on its 
rate of generation than by its elimination. Assuming type of cytokine with a plasma 
half-life of ten minutes, a SC of 0.5 in 5 l of blood volume and with hematocrit 0.30 
metabolic clearance can be estimated to be about 200 ml/min which is much more than 
clearance of a healthy kidney, which may be estimated as 60 ml/min. Clearance of CHF 
with 40 l of filtrate per day will be about 13 ml/min. Consequently removal of cytokines 
using CHF is inconsiderable.  
Another aspect of HVCHF is unspecificity of MM removal. Not only harmful 
substances like proinflammatory cytokines but also vital substances with low molar 
concentration like anti-inflammatory cytokines and hormones might be removed. 
Therefore specific absorption seems to be the only method to remove proinflammatory 
cytokines effectively. Plasma filtration coupled with sorbent absorption has 
demonstrated substantial removal of all kinds of cytokines in an in-vitro study [33, 119]. 
Further studies are necessary to clarify if cytokine removal in septic patients with ARF 
is feasible. 
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6.3 Prescription of continuous hemofiltration 
 
Prescription of the dose of continuous hemofiltration is performed in terms of filtration 
rate per unit of time. It has to take into account the indication of CHF, special data of 
the individual patient and performance data of the hemofilter. The hemofilter itself 
should be capable of running at least 24 hours. The individual dose of filtration therapy 
should be related to the body weight of the patient. 
If there is only ARF without sepsis or intoxication with specific protein bound or non-
protein bound toxins a dose of CHF of 20 ml/(h·kg) equivalent to about 25  ~ 35 l of 
filtrate per day seems to be adequate. This also has been shown in our study where urea 
and creatinine concentration in the blood of the patients were in an acceptable range 
(see Table 3). If one has in mind to eliminate more middle molecular weight toxins e.g. 
cytokines, higher amounts of filtrate of about 40 ml/(h·kg) or about 55 ~ 75 l/day are 
necessary. 
Table 8 shows a comparison of urea clearance in one patient in different modes of 
hemodialysis and filtration therapy in relation to clearance of the normal kidney. In this 
table Kt/V of continuous and intermittent therapy only with some constraints is 
comparable. Nevertheless it shows that CHF even with 20 ml/(h·kg) is much more 
efficient than standard HD. It is nevertheless far from achieving the efficiency of the 
natural kidney. 
 Machine 
setting/Perfusion 
K 
(l/hr) 
t (h/week) K (l/week) 
Kt /V    
per week 
Kt /V 
per day
HD 
Qbi = 200 ml/min     
Qd = 500 ml/min 
10.8 13.5 146   3.7 1.2 
Qf = 20 ml/(h•kg) 1.36 168 228   5.7 0.8 
Qf = 35 ml/(h•kg) 2.38 168 400 10.0 1.4 CHF 
Qf = 45 ml/(h•kg) 3.06 168 514 12.9 1.8 
Normal 
kidney 
Qbi = 1000 ml/min,   
Qf  = 111 ml/(h•kg) 
7.5 168     1 260 31.5  4.5 
 
Table 8: Comparison of urea clearance and Kt/V among HD, CHF and 
healthy kidney. V: urea distribution volume is assumed for 40 l, HD: 
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intermittent hemodialysis, CHF: continuous hemofiltration, K: urea 
clearance, t: treatment time, Qf: ultrafiltration rate, Qbi: blood flow rate, 
Kt/V: dose of therapy calculated with urea clearance, time and urea 
distribution volume (not from pre- & post- dialysis urea concentration), the 
assumption is made in the case of SCurea = 1. 
 
The amount of filtrate per unit of time, which has to be set to an individual patient 
depends on the blood flow of the patient available for CHF therapy and the body weight 
of the patient as has been shown by Ronco [99]. Filtration fraction should not be < 20 % 
of blood flow in order to avoid clotting.  
The hemofilter has to be chosen in order to guarantee an adequate filtration rate and an 
UFR/Area < 1500 ml/ (h·m2). This implicates that in the data sheet of each hemofilter 
the maximum ultrafiltration rate below this value should be indicated. 
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Figure 20:  Selection of hemofilters depending on patients’ body weight.  
 
In order to understand this in more medical way, three lines represent three 
ultrafiltration doses in Figure 20. Ultrafiltration rate setting has to be relevant to 
patients’ body weight when one ultrafiltration dose is selected. The daily amount of 
filtrate depending on body weight and indication may be found out by using this figure. 
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7 SUMMARY 
 
Continuous hemofiltration is a method to treat acute renal failure. Different from 
intermittent treatment of end stage renal failure, blood is exposed to the surface area of 
the hemofilter membrane for up to several days. It is a matter of debate how long the 
hemofilter membranes can maintain their initial properties to separate water and specific 
toxins from blood of the patients. 
It was the aim of this study to evaluate permeability of water and solutes between MW 
10 000 to MW 70 000 in vivo during the whole time of filter running. Three different 
hemofilters have been investigated. 
The hydraulic permeability of each filter continuously declines and a linear increase of 
transmembrane pressure is necessary to keep filtration rate constant. This effect of 
decreasing hydraulic permeability is more pronounced in the hemofilter with highest 
ultrafiltration rate per membrane area (UFR/Area) and negative charge of the 
membrane polymer. Filter running time (FRT) is exponentially related to UFR/Area. 
Decrease in hydraulic permeability is attributed to membrane fouling. 
It is concluded that FRT can be optimized keeping UFR/Area below 1500 ml/ (h·m2). 
Dose of continuous hemofiltration and the choice of the hemofilter should be related to 
body weight of the patient and available blood flow.  
In all filters total protein is found in the filtrate only in the first hours of treatment. After 
5 hours, it is less than 50 mg/l corresponding to 1.5 ~ 2.0 g/day. Loss of albumin is less 
than 100 mg/day. 
Middle molecules in the range of MW 10 000 to MW 40 000 are found in the filtrate 
until the end of filter running. Theoretically also cytokines can be removed by 
continuous filtration. 
Secondary membrane formation (membrane fouling) with decreasing hydraulic 
permeability does not exclude permeability of molecules in the range of MW 10 000 to 
40 000. Effective removal of proinflammatory cytokines in septic patients is considered 
to be rather unlikely. 
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7    ZUSAMMENFASSUNG 
 
Die kontinuierliche Hämofiltration ist eine Methode zur Behandlung des akuten 
Nierenversagens. Im Gegensatz zur intermittierenden Hämodialysebehandlung ist das 
Blut des Patienten hierbei mit der Membran des Hämofilters mehrere Tage in Kontakt. 
Es stellt sich daher die Frage, wie lange die Hämofilter-membran ihre ursprünglichen 
Eigenschaften zur Abtrennung von Wasser und Toxinen vom Blut des Patienten 
aufrechterhalten kann. 
Es war das Ziel dieser Studie, die Permeabilität von Wasser und gelösten Substanzen im 
Bereich des Molekulargewichts von 10 000 bis 70 000 in-vivo während der gesamten 
Funktionszeit der Hämofilter zu untersuchen. Hierbei wurden drei verschiedene 
Hämofilter von verschiedenen Herstellern untersucht. 
Als Ergebnis der Untersuchung zeigte sich, daß die hydraulische Permeabilität bei allen 
Filtern kontinuierlich abnimmt und daß ein linearer Anstieg des Transmembrandrucks 
notwendig ist, um die Filtrationsrate konstant zu halten. Dieser Effekt der 
kontinuierlichen Abnahme der hydraulischen Permeabilität ist stärker ausgeprägt in den 
Filtern mit höherer Filtrationsrate pro Membranfläche und negativer Ladung der 
Membran. Die Laufzeit der Hämofilter steht in einem exponentiellen Verhältnis zur 
Filtrationsrate pro Membranfläche. Der Abfall der hydraulischen Permeabilität der 
Hämofilter wird als Folge einer Sekundärmembranbildung angesehen. 
Aus den Ergebnissen wird geschlossen, daß die Laufzeit der Hämofilter optimiert 
werden kann, indem die Ultrafiltrationsrate pro Membranfläche kleiner als 1500 ml/ 
(h·m2) gehalten wird. Die Dosierung der Hämofiltrationsbehandlung sowie die Wahl 
des Hämofilters sollte vom Körpergewicht des Patienten und vom verfügbaren Blutfluß 
abhängig gemacht werden. 
Bei allen Hämofiltern ist lediglich während der ersten Stunden der Behandlung eine 
geringe Menge an Protein im Filtrat nachweisbar. Nach 5 Stunden beträgt die 
Proteinkonzentration im Filtrat bei allen Filtern weniger als 50 mg/l entsprechend einer 
Gesamtmenge von 1,5 - 2,0 g/Tag. Der Verlust von Albumin beträgt weniger als 100 
mg/Tag. Mittelmolekulare Urämietoxine mit einem Molekulargewicht von 10 000 bis 
40 000 finden sich hingegen während der gesamten Laufzeit der Hämofilter im Filtrat. 
Somit können theoretisch auch Zytokine über eine kontinuierliche Hämofiltration 
ausgeschieden werden. 
Die Sekundärmembranbildung im Laufe einer Behandlung mit nachlassender 
hydraulischer Permeabilität schließt aber nicht die Permeabilität mittelmolekularer 
Urämietoxine aus. Eine effektive Entfernung proinflammatorischer Zytokine erscheint 
aber aus kinetischen Überlegungen als unwahrscheinlich.
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8 APPENDIX 
 
Qb: Inflow blood flow rate; Qd: dialysing fluid; UFR/Area: ultrafiltration rate per area; UFH: Unfractionated heparin; FRT: 
Filter running time; SA: Surface area; PSu: Polysulfone; ST: surface treated; n.a.: Not available; m: maintenance; b: bolus 
 CRRT modes 
Qb 
(ml/min) 
Anti-Coagulation 
method 
Hemofilter 
UFR/Area 
(ml/h • m2) 
Def. of end point 
of FRT 
FRT (h) 
168.8 ; 
1.5 Pre-CVVH 
850; 
6425 
Mokrzyck et 
al. [84],1996   
7 patients; 22 
filters 
Pre-CVVHD/F 
100~300 
 
UFH 
F-80® (PSu, 1.8 
m2); 
Amicon-20® (PSu, 
0.25 m2) 202; 
7250 
n.a. 
19.5; 
2.5 
Pre-CVVH 18 
Uchino et al. 
[125],2003  
48 patients; 
309 filters Post-CVVH 
200 
UFH,m: 5~10 
IU/(kg•h) 
AN69® or 
APSu650® (1.3 m2) 
1538.5 
Mainly by filter 
clotting 
13 
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40 UFH, m: 1000 IU/h 
heparin Mochi et al. 
[85], 2004; 
47 patients, 
Post-CVVH 175 
RCA, (CCa2+ < 
0.3mmol/l) 
Arylane H6® (PSu) 
1,6 m2 
1562.5 
Spontaneous 
failure (clotting or 
TMP > 300 
mmHg) 70 
Pre-CVVH 45.7 
Van der 
Voort et 
al.[130], 
2005; 16 
patients; 32 
filters 
Post-CVVH 
200 
Nadroparin (2850 IU 
bolus and 475 IU/h 
continuous infusion) 
CT. 190G® 
(Cellulose tri-
acetate) 1,9 m2 
1578.9 
TMP reaches 
250mmHg 
16.1 
28 
Pre-CVVH 140 
De Pont et al. 
[31], 2006; 8 
patients, 15 
filters Post-CVVH 200 
Nadroparin (2850 IU 
bolus and 456 IU/h 
continuous infusion) 
CT. 190G® 
(Cellulose tri-
acetate) 1,9 m2 
1894.7 
TMP reaches 450 
mm Hg; prefilter: 
400 mmHg 15 
del Castillo 
et al. [34], 
CRRT (CHF and 
CHDF) 
n.a. (about 
1) 
UFH, b: 20 to 50 
IU/kg 
PSu <500 
A steep increase 
in the filter 
31 
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2008; 122 
children, 365 
filters 
pressure indicates 
clotting 
Kindgen-
Milles et 
al.[65]; 2008; 
case report 
CVVHD 150 Citrate 265 ml/h AV1000S® (PSu) 
100; 
Qd = 2 l/h 
clotting >84 
Kleger et 
al.[66]; 2010; 
38 patients, 
167 filters 
Pre-and post 
dilution 
200~300 UFH M 150® (AN 69®) 1866.7 n.a. 39.3 
 
Post-CVVH 163 + 29 
AV1000S® (PSu), 
1.8 m2 
1056.4±164 51.2 
Pre&post-CVVH 159 + 20 
ST150® (AN69 
ST), 1.5 m2 
1168±127 47.1 
Xie &Mann 
et al.; 30 
patients, 35 
filters 
Post-CVVH 143 + 18 
UFH, b: 40 IU/kg; m: 
500~1,500 IU/h to 
target ACT at 
160~200 s M 100® (AN69®), 
0.9 m2 
1916.7±314 
1. application 
time over 72 h; 2. 
TMP>250; 3. 
blood clotting 
examination of 
hemofilters every 
8 h 
16.8 
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 CRRT modes 
Qb 
(ml/min) 
Anti-Coagulation 
method 
Hemofilter 
UF/area 
(ml/h • m2) 
Def. of end point 
of FT 
FRT (h) 
31.4 Low-dose UFH 
(500IU/h) 
Bellomo et 
al.[11]; 1993, 
10patients, 
34 filters 
CVVHDF 150 
UFH/protamine 
(1000IU/h) 
AN69S®; 0.45 m2 
Variable, 
above 334; 
Qd =1 l/h 
Clotting of filter 
or UF below 150 
ml/h 40.5 
Matin et 
al.[82]; 1994, 
255 patients 
Post-CVVH 100~150 
UFH, b: 0~2000IU; m: 
0~2000IU/h 
AN69® or FH66® 
(polyamide), 0.6 m2
1333~2168 filter clotting 22.1~24.7 
32 
 
 
Tan et 
al.[117]; 
2000, 26 
patients, 40 
filters 
Pre-CVVH 200~300 No UFH for high risk 
of bleeding 
Hospal, AN69®; 0.9 
m2 
2222 
1. Failure to yield 
prescribed UFR; 
2. Visible blood 
clotting 3. venous 
pressure above 19.5 
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filters   
UFH 5~10 IU/kg/h, 
without prolongation of 
APTT 
  pressure above 
150 mmHg and 
sudden cessation 
of blood flow 
 
UFH to achieve ACT 
at 180~210s; 
28 Vargas Hein 
et al. [135]; 
2001, 17 
patients 
Post-CVVH 80~150 
Hirudin 10 μg/kg/ to be 
ECT at 80~100 
Polyflux 11S, 1.1 
m2 
1364 Clotting 
22 
UFH, b :5000IU, m : 
1000IU/h. 
42.5 Gabutti et al. 
[36] ; 2002, 
12 patients, 
89 filters 
Pre-CVVHDF 150 
RCA (0.95 < CCa2+ 
<1.05mmol/l pre-filter) 
M100® (AN69®); 
0.9 m2 
1666.7; Qd 
=0.5l/h 
An occlusive clot 
to the dialyzer 
24.2 
38.3 
 
 
Kutsogiannis 
et al.[70]; 
2005, 30 
patients, 79 
filters 
Pre-CVVHDF 125 UFH, b: 50 IU/kg, m: 
target PTT, 45~65s 
M100® (AN69®); 
0.9 m2 
1111~1444 
Filter clotting, 
surgery and 
radiology 
examination 
124.5 
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filters   RCA(0.25< CCa2+ 
<0.35 mmol/l post-
filter) 
    
32 UFH, b: 2500IU; m: 
based on ACT 
Van Doorn et 
al.[131]; 
2004, 29 
patients 
Post-CVVH 110 
Dalteparin, b: 
70IU/h,m: 40/kg/h 
F 70 (PSu); 1.6 m2 625 clotting 
30.5 
Baldwin et 
al.[7]; 2004, 
12 patients 
Pre-CVVH 200 n.a. AN69® S; 1.3 m2 1538.5 
Inability of 
drawing target 
UFR 
19.6 
Table 9: Review of relative filtration rate and hemofilter life time 
Qb: Inflow blood flow rate; Qd: dialysing fluid; UFR/Area: ultrafiltration rate per area; UFH: Unfractionated heparin; RCA: 
Regional citrate anticoagulation; ACT: Activated clotting time; FRT: Filter running time; SA: Surface area; PSu: Polysulfone; 
ST: surface treated; n.a.: Not available; m: maintenance; b: bolus
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9 INDEX OF ABBREVIATIONS 
 
ACE                      Angiotensin converting enzyme 
ACT                      Activated clotting time 
α1 M                      α1 microglobulin 
AN69®        Polyacylonitrile membrane from Hospal 
ARF         Acute renal failure  
β2 M                      β2 microglobulin 
CAPD         Continuous ambulatory peritoneal dialysis  
CAVH        Continuous arterio-venous hemofiltration 
C3b                        Complement component 3’s larger cleavage 
Cbi                                       Inlet concentration in plasma water 
Cbo                                      Outlet concentration in plasma water 
Cpre                                    Concentration of solute before treatment 
Cpost                                   Concentration of solute after treatment 
CH         Continuous hemofiltration 
CHDF         Continuous hemodiafiltration 
CHF         Continuous hemofiltration 
CRF         Chronic renal failure 
CRP                       C-reactive protein 
CRRT                    Continuous renal replacement therapy 
CVVH        Continuous veno-venous hemofiltration 
CVVHDF        Continuous veno-venous hemodiafiltration 
ECT                       Ecarin clotting time 
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ESRD         End stage renal disease 
EPO                       Erythropoietin 
FRT                        Filter running time 
GFR          Glomerular filtration rate 
HD          Hemodialysis 
HDF          Hemodiafiltration 
HF          Hemofiltration 
HIT                        Heparin-induced thrombocytopenia  
HVHF                    High-volume hemofiltration 
ICU                        Intensive care unit 
IFN-γ                     Interferon gamma 
IgG                         Immunoglobin G 
IL                           Interleukin 
K         Clearance 
Kt/V          Dose of dialysis in terms of urea clearance, treatment time  
           and urea distribution volume 
Lh                                         Hydraulic permeability 
LPS                         Lipopolysaccharides 
MEIA          Microparticle enzyme immuno assay  
MM                        Middle molecules 
MOF          Multi-organ failure 
MW          Molecular weight 
PA          Polyamide 
PAN                       Polyacrylonitile 
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PEI                          Polyethylene-imine 
PD           Peritoneal dialysis 
PMMA          Polymethylmethacrylate 
PR                            Percentage reduction 
PTT                         Patial thromboplastin time 
PSu           Polysulfone 
PU           Polyurethane 
RBP                         Retinol binding protein 
RCA                         Regional citrate anticoagulation 
SC            Sieving coefficient 
SDS             Sodium-dodecyl-sulphate  
SDS-PAGE           Sodium-dodecyl-sulfate-polyacrylamide-gelelectrophoresis 
SIRS                        Systemic inflammatory response syndrome 
TAT                         Thrombin-antithrombin III 
TCA                         Trichloracetic acid 
TNF-α                      Tumor necrosis factor alpha 
TMP                         Transmembrane pressure 
UFcoeff                                  Ultrafiltration coefficient 
UFH                         Unfractioned heparin 
UFR                         Ultrafiltration rate 
UFR/Area                Ultrafiltration rate per area 
UFH                          Unfractionated heparin 
URR            Urea reduction ratio
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